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ATHEROSCLEROSIS: AN OVERVIEW 
 
Atherosclerosis (athero = soft gruel-like deposit, and sclerosis=hardness) is 
complex pathology that involve deposition of cholesterol, fats, cellular 
metabolites, calcium and various other substances on the inner lining of 
the artery1.  This disease of the large arteries is the primary cause of heart 
disease and stroke, and is the underlying cause of about 50% of all 
deaths in westernized societies2.  In 2002, the most recent year for which 
worldwide data from the World Health Organization3 are available, 
global mortality due to CVD was estimated at 16.7 million deaths. Of 
these, CHD was the single most important cause identified, accounting 
for 7.2 million (43%) deaths. Stroke accounted for an additional 5.5 million 
(33%) annual deaths. The remaining cardiovascular deaths were due to 
hypertensive, inflammatory, or rheumatic heart diseases, or other forms, 
such as tumors of the heart, vascular tumors of the brain, disorders of 
heart muscle/cardiomyopathy, heart valve disorders, and disorders of 
the lining of the heart3. The incidence of CHD mortality has increased 
since 1990 as life expectancies have risen.  Although CHD death rates 
have declined in western countries in response to improvements in 
disease management, rates are expected to increase in developing 
countries in the future3. 
Under a very precise and literary point of view, arteriosclerosis can be 
defined as a chronic disease characterized by abnormal thickening and 
hardening of the arterial walls with resulting loss of elasticity, whereas 
atherosclerosis is characterized by atheromatous deposits in and fibrosis 
of the inner layer of arteries. Hence atherosclerosis can be considered as 
an advanced stage of arteriosclerosis, since plaque formation comes at 
later stages of the disease1. Atherosclerosis initiating event may be 
different under different condition, but it is suggested that endothelial 
dysfunction is one of the major event. Such a dysfunction may occur 
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due to many factors (e.g. vessel injuries and collagen exposure, 
metabolite deposition in the vessel wall, change in vascular reactivity 
due to change in the rate or the force of blood flow) 1. 
Atherosclerotic lesions begin as fatty streaks underlying the endothelium 
of large arteries. In humans, fatty streaks can be found in the aorta in the 
first decade of life, the coronary arteries in the second decade, and the 
cerebral arteries in the third or fourth decades2.  They consist of smooth 
muscle cells (SMCs), lymphocytes and mainly of macrophages4. The 
formation of fatty streaks is initiated by adherence of circulating 
monocytes to activated endothelial cells at lesion-prone sites within the 
arteries.  Adherent monocytes subsequently migrate into the 
subendothelial space in response to locally produced chemo-attractant 
molecules, where they further differentiate into macrophages and start 
to accumulate lipids (mainly cholesterol esters) by the interaction with 
modified low density lipoprotein (LDL)4. When macrophages take up 
more lipoprotein cholesterol than they can excrete, the cholesterol is 
stored in the cytoplasm by means of cholesteryl esters droplets. These 
droplets give the cytoplasm a foamy appearance at electron 
microscope observation, thus accounting for the term of foam cells5. 
Then, fatty streaks could progress and develop into advanced 
atherosclerotic plaques. The American Heart Association (AHA) 
Committee on Vascular lesion provided a pathobiological nomenclature 
and classification of human atherosclerotic lesions, dividing them in 6 
stage of development (from type I to type VI)6, 7. Lesions type I, II and III 
are the silent precursors of types IV, V and VI, advanced plaques 
associated with clinical events (see FIGURE 1 and TABLE I).  
The development of atherosclerotic plaques occurs after LDL 
accumulation within the sub-endothelial matrix of artery wall, leukocyte 
extravasation, foam cell formation, smooth muscle cell proliferation and 
connective tissue production8. With the secretion of fibrous elements by 
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SMCs, occlusive fibrous plaques develop and increase in size2. Low 
density lipoproteins represent the main source of cholesterol not only for 
peripheral tissues but also for arterial wall.  Moreover it has been 
demonstrated that accumulation of LDL in blood vessels is greater when 
level of circulating LDL are raised, and both transport and retention of 
LDL are increased in the preferred sites for lesion formation2.  
 
 
 
 
FIGURE 1 - Different stages in progression of atherosclerosis (from9) 
 
LDL diffuse passively through endothelial cell (EC) junction and their 
retention in the arterial wall seems to involve interaction between the 
extracellular matrix and the apolipoprotein B (apoB), which is the major 
protein component of low density lipoprotein. An ionic interaction of 
positively charged regions of apolipoprotein (apo) B with matrix proteins, 
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including proteoglycans, collagen, and fibronectin, is thought to initiate 
the LDL retention process10.  In addition, other apoB-containing particle 
(i.e. lipoprotein (a) and remnants), can accumulate in the intima and 
promote atherosclerosis2.  It has been shown that native LDL is not able 
to load macrophages so rapidly to transform them into foam cells, and 
so it was proposed that LDL, trapped within vessel wall, does undergo 
modification, including oxidation, lipolysis, proteolysis and aggregation. 
Such modifications contribute to inflammation as well as foam cell 
formation2.  Macrophages within atheroma show a substantial 
upregulation of the scavenger receptor that normally function in the 
recognition and internalization of pathogens and apoptotic cells. Brown, 
Goldstein and co-workers gave it the name of “scavenger receptor” (SR) 
to distinguish the uptake of modified LDL by macrophages from LDL 
uptake via the classical LDL receptor (LDLr) which, in contrast with SR, is 
feedback inhibited by cellular cholesterol accumulation5, 11. The most 
frequently studied modification of low density lipoprotein is the oxidation, 
that in-vivo seems to occur by the action of several enzymes, such as 
NAD(P)H oxidase, xanthine oxidase, mieloperoxidase, nitric oxide 
synthase (NOS), lipoxygenase and mitochondrial electron transport 
chain12. In vivo it has been shown that products derived from oxygen, 
chlorine, nitrogen and lipid peroxidation induced free radicals are the 
major oxidants involved in oxidized LDL (oxLDL) formation. Consistently 
with the demonstrated role of oxidative stress and oxLDLs in 
atherosclerosis, it has been shown that variable levels of oxLDL are 
detectable in human plasma and F2-isoprostanes (IsoPs) can be 
measured in human body fluids such as plasma and urine using highly 
precise methods. The F2-IsoPs represent, in 2005, the most established 
index of oxidative stress status in vivo in humans13. Both these factors are 
proposed and considered as strong and independent risk factors for 
coronary heart disease (CHD) 14, 15. It has been proposed that OxLDLs 
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exert their atherogenic activity not only inducing foam cells formation, 
but also by means of a proinflammatory, immunogenic, cytotoxic and 
apoptotic activity. They are shown to stimulate adhesion molecule 
expression in endothelial cells, resulting in increased monocyte 
recruitment. Moreover OxLDLs seem to promote monocyte 
differentiation, to stimulate in macrophages the production and 
secretion of proinflammatory cytokines and chemokines, and to inhibit 
macrophage migration ability2, 16. As mentioned above, low density 
lipoproteins, trapped inside atheroma, undergo several modification 
reactions leading to atherogenic compounds: it has been demonstrated 
that LDL glycation is at least as important as oxidation in atherogenesis 
(for review see17). It has been shown that both glycated LDL (glycLDL) 
and oxLDL were localized in macrophage-derived foam cells in the 
atherosclerotic lesions with the native LDL confined to the extracellular 
matrices. Glycation and oxidation of LDL probably take place 
simultaneously in vivo, leading to additional modification of LDL (i.e. 
Glycoxidated LDL)17. Post-secretory glycation of proteins is a process of 
non-enzymatic condensation of glucose with proteins to form stable 
covalent adducts leading to structural alterations and, consequently, to 
functional abnormalities. 
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TABLE I – Classification of human atherosclerotic lesions 
Type I The inner lining of the normal coronary artery is smooth 
and free of blockages or obstructions 
Type II With increasing age, lipids or fatty substances 
(cholesterol and triglycerides) are deposited as fatty 
streaks which are only minimally raised and do not 
produce any obstruction or symptoms. This is just the 
beginning of atheroma. 
Type III Further increase in builtup of fatty layers, atheroma, 
begins to encroach the inner channel which starts 
interfering with the free blood flow through coronary 
artery, thereby exposing the person to more risk of 
coronary artery disease 
Type IV With fibers beginning to grow in the fatty layers of the 
atheroma, the blockages harden into plaques, which 
increase the encroachment in the inner channels of 
the coronary artery. This encroachment may be up to 
50% or more of its diameter and leads to obstruction 
sufficient to decrease the blood flow of heart muscle, 
even in the time of its increased need (exercise, 
emotional stress). This leads to elevation in blood 
pressure and heart rate. 
Type V In some cases, plaques within the inner lining of the 
coronary artery may develop a slight crack or rupture, 
which stimulates the production of blood clots. The 
clots also get into the crack and cause it to rise and 
further obstruct the channel of the artery. The supply of 
the blood flow to the heart muscle is substantially 
reduced and the patient begins to have severe and 
prolonged chest pain that occurs at rest. This is known 
as unstable angina. 
Type VI In case the clot does not fully close the channel of the 
artery and sufficient blood flow is maintained to the 
heart muscle, a heart attack may not develop, 
provided appropriate and prompt treatment is 
effected. However, the clot may continue to grow in 
many cases. This can completely fill the open channel 
of the artery and cutoff blood flow to the part of the 
heart muscle to which it is supplying. 
Created and adapted by using classification from9 
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The non-enzymatic glycation of LDL takes place principally in apoB. 
Lysine is the major amino acid that undergoes glycation with 2–17% of 
LDL–lysine residues being glycated. Because of their glycemic status, 
diabetic patients showed higher serum levels of glycated apoB and 
glycLDL compared to non diabetic subjects, but high levels of serum 
glycLDL were also found in hyperlipidemic non diabetic patients17.  
Ischemia, a restriction in blood supply, is one of the most frequent clinical 
manifestations associated to atherosclerosis, and the loss of luminal 
diameter secondary to plaque growth seems to not be the major 
determinant for ischemic event. In fact, it has been known for 20 years 
that there is a compensatory adaptive enlargement or "positive 
remodeling" of atherosclerotic human coronary arteries, with 
preservation of the cross-sectional area of the lumen in the early stages 
of the disease process. This knowledge is based on the findings of 
autopsy studies that demonstrated that the coronary lumen did not 
decrease in size until the atheroma occupied >40% of the area 
encompassed by the outside wall of the artery18. Pathological studies 
suggest that the development of acute coronary events depends 
principally on the composition and vulnerability of the plaque rather 
than severity of stenosis. Hence, the fibrous cap weakening seems to be 
a key role player in ischemic attack genesis. Several evidences have 
supported the concept that the protective fibrous cap, far from being 
fixed and static, actually can undergo continuous and dynamic 
remodeling and displays considerable metabolic activity. The 
progressive erosion of this element could cause the partial or the total 
rupture of atherosclerotic plaque, leading to the activation of 
coagulation cascade and thrombus formations.  Thrombosis represents 
the final stage of atherosclerosis and leads to clinical manifestations and 
adverse events in the coronary, cerebro-vascular and vascular 
disctrict19. 
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COMPLEX AETIOLOGY: INFLAMMATION AND DYSLIPIDEMIA  
 
Over the past 50 years, epidemiological studies have shown what kind of 
complexity is behind atherosclerosis, revealing a very large number of risk 
factors involved2. These can be divided into factors with an important 
genetic component, and those that are largely environmental. The 
relative abundance of the different plasma lipoproteins appears to be of 
primary importance, since raised levels of atherogenic lipoproteins are a 
prerequisite for most forms of the disease2. Each of the genetic risk 
factors involves multiple genes. Experimental studies with genetic crosses 
in animals maintained under similar environmental conditions could 
clearly show this complexity. Such studies in rodents have revealed 
dozens of genetic loci that contribute to lipoprotein levels, body fat and 
other risk factors. Moreover, the interactions between risk factors 
increase the complex aetiology. Frequently, these are not simply 
additive (e.g. the effects of hypertension on coronary heart disease 
(CHD) are considerably amplified if cholesterol levels are high).2 The 
importance of genetics and environment in human CHD has been 
examined in many family and twin studies, and it has been shown that 
the common forms of CHD result from the combination of an unhealthy 
environment, genetic susceptibility and our increased lifespan2. The 
concept that atherosclerosis is a chronic inflammatory disease, initiated 
by monocytes adhesion to activated endothelial cells,  is widely 
accepted and has been confirmed  by several clinical and experimental 
observation2, 4, 20, 21. “Inflammation is a complex set of interactions 
among soluble factors and cells that can arise in any tissue in response to 
traumatic, infectious, post-ischaemic, toxic or autoimmune injury”22 and 
seems to be involved in every stage of atherosclerosis. During fatty 
streaks formation, endothelium activation results in secretion of 
chemokines (e.g. MPC-1 and IL-8), adhesion molecules (e.g. ICAM-1, 
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VCAM-1, E-selectin, P-selectin). These molecules enhance monocyte 
and lymphocyte recruitment and infiltration in the sub-endothelial 
space21. Inflammation seems to play an important role also in the final 
stage of the pathology, when clinical events occur. Cells inside plaque 
secrete matrix metal proteases (MMPs), which degrade the cellular 
matrix protein leading to fibrous cap weakening23. Moreover every cell 
types involved in atherogenesis (i.e. endothelial cells, SMC, 
monocytes/macrophages, lymphocytes (T, B, NKT), dendritic cells, and 
mast-cells) secrete or are stimulated by peptides, glycoproteins, 
protease and cytokines. 
Though inflammation allows understanding several mechanisms involved 
in atherosclerosis, it must be reminded that lipid accumulation is an 
essential factor for the development of this disease. Moreover, as 
mention above, raised levels of atherogenic lipoproteins appears to be 
of primary importance. Dyslipidemia can be defined as the disorder of 
lipid metabolism leading to an increase (hyperlipoproteinemia) or a 
decrease (hypolipoproteinemia) of plasma lipoprotein, often associated 
with their qualitative alteration. The role of plasma lipoproteins in 
atherosclerosis came under study more than 50 years ago, at the same 
time as epidemiologic data linking cholesterol and heart disease were 
becoming available24. The lipid hypothesis, which described the role of 
dietary saturated fat in raising serum cholesterol and the risk of CHD, 
could not be adequately tested because the treatment options of the 
time—fibrates, anion-exchange resins, and nicotinic acid—were limited 
in efficacy and poorly tolerated24, 25. Key discoveries in the 1970s, 
including the identification of the hepatic LDL-C receptor and 
characterization of hepatic hydroxymethyl glutaryl coenzyme A (HMG-
CoA reductase), the enzyme that controls the rate of cholesterol 
biosynthesis, led to development of HMG-CoA reductase inhibitors, 
beginning with lovastatin and simvastatin in the 1980s24, 26-30. Clinical trials 
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in the 1990s confirmed the lipid hypothesis and established LDL-C as the 
primary treatment target24, 25, 31. A publication from the Reduction of 
Atherothrombosis for Continued Health (REACH) Registry of patients 
(N=67,888) with stable atherosclerotic clinical syndromes highlights that 
hypercholesterolemia is prevalent, yet undertreated, and correlated 
generally with cardiovascular event rates around the world32, 33. It was 
shown that substantial proportions of these patients had total cholesterol 
levels above 5.18 mmol/L (200 mg/dL), with a high of 64.4% in Eastern 
Europe.  Such high rates of hypercholesterolemia are remarkable 
because more than 75% of these patients were receiving lipid-lowering 
therapy, predominantly statins. Since 1994, 8 placebo-controlled trials 
that enrolled 67,462 patients with dyslipidemia have evaluated the 
efficacy of statin therapy for the primary or secondary prevention of 
CHD events. In these trials, LDL-C reductions ranging from 25% to 35% 
corresponded with relative risk reductions of 24% to 40% for CHD death or 
nonfatal myocardial infarction25, 34-41, suggesting that, despite the good 
improvement, a substantial risk of CHD events remains. 
Substantial epidemiologic evidence suggests a negative linear 
correlation between HDL-C levels and the incidence of CHD. An inverse 
relationship between HDL-C and coronary artery disease (CAD) was 
established in the Framingham study in the 1970s. This analysis of 2815 
men and women aged 49–82 years identified HDL-C as a powerful risk 
factor inversely associated with the incidence of CAD42. Similarly, in the 
early 1980s, the Prospective Cardiovascular Munster (PROCAM)study43 
evaluated 4559 male participants aged 40–64 years and found a strong 
negative linear correlation between the incidence of CAD and HDL-C 
levels (CHD risk ratio of 4.0 for HDL-C <25 mg/dL versus 1.0 for HDL-C >65 
mg/dL, p < 0.001). Different prospective studies has estimated a 2% 
(men) and  3 % (women) increase in cardiovascular risk for every 1 
mg/dL reduction in serum HDL-C44. A post hoc analysis45 of the Treating 
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to New Targets (TNT) study46 was conducted to evaluate the predictive 
value of HDL-C for the 5-year risk of major CV events. It was showed that 
HDL-C was a significant predictor of major CV events (P=0.05) across the 
population of statin-treated patients with CHD, and high levels of HDL-C 
significantly reduced the 5-year risk of major CV events (P=0.03), even in 
patients with low LDL-C (<70 mg/dL) 45. The finding that HDL-C remained 
a significant predictor of major CV events in patients with very-low LDL-C 
supports the clinical relevance of HDL-C as a therapeutic target. Statin-
treated patients who achieve a low LDL-C goal still have a substantial 
residual risk that can perhaps be reduced by increasing the HDL-C 
concentration45. In 2006, the phase III clinical trial ILLUMINATE 
(Investigation of Lipid Level Management to Understand its Impact in 
Atherosclerotic Events) was prematurely terminated because of an 
increased risk of death and cardiac events in patients receiving 
torcetrapib47, a novel drug targeted to cholesterol ester transfer protein 
(CETP) inhibition to increase HDLc. The CETP inhibition approach is still 
widely debated, and the particular concern is if the deleterious effect of 
torcetrapib resides in its intrinsic properties (failure of the molecule) or the 
whole concept of CETP inhibition is erroneous (failure of the 
mechanism)48-51. One interesting concept that has also been highlighted 
is  the complexity of the relationship between HDL and protection from 
cardiovascular disease. Functionality has become an important factor 
for consideration in the development of new agents that raise HDL-
cholesterol. The most important function of HDL is its ability to facilitate 
cholesterol efflux from peripheral cells, particularly macrophages and 
foam cells, and enhancing reverse cholesterol transport (RCT). Recently 
it has been demonstrated by in-vitro cellular cholesterol efflux assay that 
in murine peritoneal macrophages foam cells the ABCA1-mediated 
efflux to human serum contributes 80% of the stimulated component of 
total cholesterol efflux, with ABCG1-mediated efflux responsible for the 
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remaining 20% of the stimulation of efflux52. Very similar results were also 
obtained using in vivo mouse RCT assays53. Thus apolipoprotein A-I 
(apoA-I), the apolipoprotein of nascent HDL and the preferred acceptor 
for ABCA1 mediated efflux (see below), seems to play a central role in 
cholesterol efflux, consistent with their value in predicting cardiovascular 
risk (for review see54).  
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LIPOPROTEIN METABOLISM 
 
Cholesterol, triglycerides (TG, known also as triacylglycerols) and 
phospholipids (PL) are the major plasma lipid compounds, whereas 
fewer amount of other lipophilic compounds, such as lipophilic vitamins 
and hormones, are detectable. Since their lipophilic nature, they are 
internalized and carried through blood stream by macromolecular 
complexes called lipoprotein, resulting from lipid binding to specific 
protein called apolipoprotein. Liver and intestine are the main organs 
responsible for lipoprotein synthesis and secretion. Lipoproteins are 
globular particles characterized by high mass. They consist of a central 
non-polar nucleus (mainly rich in TG and cholesteryl esters (CE)) which is 
enveloped by a polar membrane made up of PL, proteins and free 
cholesterol (FC). Lipoprotein differs one from each other because of 
density, apolipoprotein and lipid composition. The apolipoprotein 
content is an extremely important factor for lipoprotein metabolism. 
Apolipoproteins act indeed not only as structural component, but as 
enzymatic cofactors and receptor binding element. Lipoproteins can be 
isolated from plasma by density ultracentrifugation and be classified as 
follow to: 
• Chylomicrons and remnants 
• Very Low density lipoprotein (VLDL) 
• Intermediate density lipoprotein (IDL) 
• Low density lipoprotein (LDL) 
• High density lipoprotein (HDL) 
 
The handling of lipoproteins in the body is referred to as lipoprotein 
metabolism, and in physiological condition it contributes to maintain 
body lipid homeostasis. It is divided into two pathways, exogenous and 
endogenous, depending in large part on whether the lipoproteins in 
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question are composed chiefly of dietary (exogenous) lipids or whether 
they originated in the liver (endogenous). 
 
ENDOGENOUS PATHWAY 
In order for the body to make use of dietary lipids, they must first be 
absorbed from the small intestine. Since these molecules are oils, they 
are essentially insoluble in the aqueous environment of the intestine. The 
solubilization (or emulsification) of dietary lipids is therefore accomplished 
by means of bile salts, which are synthesized from cholesterol in the liver 
and then stored in the gallbladder; they are secreted following the 
ingestion of fat. The emulsification of dietary fats renders them accessible 
to pancreatic lipases (primarily lipase and phospholipase A2 (PLA2). These 
enzymes, secreted into the intestine from the pancreas, generate free 
fatty acids and mixtures of mono- and diacylglycerols from dietary 
triglycerides. Pancreatic lipase degrades triglycerides at the 1 and 3 
positions sequentially to generate 1,2-diacylglycerols and 2-
acylglycerols. Phospholipids are degraded at the 2 position by 
pancreatic PLA2 releasing a free fatty acid and the lysophospholipid. The 
products of pancreatic lipases then diffuse into the intestinal epithelial 
cells, where the re-synthesis of triglycerides occurs. Dietary 
triacylglycerols and cholesterol are conjugated with several 
apolipoprotein (e.g. apoB-48, apoC-I, apo-CIII) and incorporated into 
nascent chylomicrons. These are synthesized by intestinal epithelial cells 
and then secreted into the blood through lymphatic system. In the 
bloodstream, HDL particles transfer apoC-II and apoE to the nascent 
chylomicrons. ApoE, interacting with plasma membrane heparan sulfate 
proteoglycans, binds chylomicron with endothelial cells and  by  apoC-II, 
chylomicrons activate lipoprotein lipase (LPL). LPL catalyzes a hydrolysis 
reaction that ultimately releases glycerol and fatty acids from the 
chylomicrons. Glycerol and fatty acids can be absorbed in peripheral 
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tissues, especially adipose and muscle, for energy and storage. After 
removal TG removal from the non polar nucleus of chylomicrons, by the 
action of apoC-I and apoC-III particles leave endothelial cells and start 
to exchange apolipoprotein with the other lipoprotein present in the 
blood stream. This phase results in the formation of a new lipoprotein 
called remnant chilomicron enriched in CE, apoB-48 and apoE. Through 
apoE binding to specific receptors (about 50% LDLr) on hepatocytes, 
remnants are taken up by the liver by endocytosis and then degradated 
in lysosomes. Experimental studies by electronic microscopy have shown 
a new possible pathway (LDLr independent) for hepatic uptake of 
remnants55. Remnants pass through endothelial cell-fenestrae to the 
space of Disse where they bind initially to proteoglycan-bound apo E 
and hepatic lipase as well as LDLR, all of which are anchored to the 
microvillar membrane. Proteoglycan-bound hepatic lipase binds and 
hydrolyzes remnant-lipids, increasing exposure of the endocytic 
receptor-binding domain of apo E. Additional proteoglycan-bound apo 
E on microvilli acquired by the remnants increases the affinity of the 
remnant particles for LDL receptor related protein (LRP)55.  
 
ENDOGENOUS PATHWAY 
Newly synthesized hepatic triacylglycerols and cholesterol, as well as 
dietary triacylglycerols and cholesterol, are assembled with apoB in the 
liver to form VLDL. The synthesis of VLDL has been extensively studied in 
cultured hepatic cell system56-59. By the results of these studies, a two-step 
models of VLDL assembly has been proposed60.  1. In the first step, pre-
VLDL is synthesized in the presence of lipids. In this step APOB is 
cotranslationally lipidated with the assistance of the microsomal 
triglyceride transfer protein (MTTP) that acts both as a lipid transporter 
and as a chaperon61-63. This process takes place in the endoplasmic 
reticulum. During the second step, mature VLDL is formed by bulk lipid 
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addition via fusion of pre-VLDL with large TG droplets. The confinement 
of the second step is under debate and both Golgi apparatus64 and 
smooth ER64, 65  have been implicated. Finally, in the absence of lipids the 
nascent APOB is degraded (III). The two-step model is compatible with 
the idea that the availability of lipids determines the stability of APOB. In 
agreement with this hypothesis, it was shown that unlipidated or 
underlipidated APOB is the subject of presecretory proteasomal 
degradation66-68. VLDLs secreted by human hepatocytes ranges from 
350 Å to 700 Å depending on the amount of TG in the lipid core. There 
are two secretion-competent subclasses of VLDL particles: large buoyant 
TG-rich VLDL 1 and smaller, denser and cholesteryl ester rich VLDL2.  The 
VLDL particles secreted by the liver pass through a number of 
remodeling steps in the circulation involving lipolysis and protein transfer 
through LPL and HL, giving rise to IDLs and ultimately LDL.  Remaining 
VLDL can be removed from the circulation by the hepatic uptake 
mediated by LRP and the VLDL receptor (VLDLr). LDL lipoproteins, mainly 
cholesterol enriched, interact with LDLr that is expressed in every 
mammalian cells and bind to apoB-100 and apo-E present in LDL. After 
binding to LDLr, LDL undergo endocytosis and then are internalized into 
lysosoms, where the acid lipases hydrolyze CE. Thus, free cholesterol is 
available for membrane needs, steroid hormone synthesis and storage 
(after re-esterification by the ACAT enzyme (for details see below)). 
Before the interaction with LDL receptor, low density lipoproteins can be 
modified by the action of cholesterol ester transfer protein (CETP) that 
transfer cholesterol ester (CE)  
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 TABLE II - LIPOPROTEIN CLASSIFICATION AND FEATURES 
CLASS Density 
(
 
 
 
from HDL to LDL (only when hypertriglyceridemia is present, to VLDL69) in 
exchange for triglyceride (TG), and viceversa70. LDLr mediated cellular 
cholesterol influx results in a reduction of cellular cholesterol synthesis, 
reduction in LDLr expression and increase of CE synthesis. The intracellular 
and membrane amounts of fatty acids and cholesterol are constantly 
coordinated with de novo lipid synthesis which is controlled by the 
transmembrane sterol regulatory element binding proteins (SREBPs) 71. In 
the presence of cholesterol or oxysterols, SREBP, SCAP (SREBP cleavage 
activating protein) and INSIG (insulin inducible gene) form a complex 
which is retained in the ER. When the concentration of cellular sterols is 
low, INSIG is released from SREBP-SCAP which is  transported to the Golgi 
apparatus where SREBP undergo two sequential proteolytic cleavages 
by Site-1 and Site-2 proteases72. SREBP-1a, SREBP-1c and SREBP-2 proteins 
are encoded by 2 unique genes (i.e. SREPBF-1 and SREPBF-2) and belong 
to the SREBP family of basic-helix-loop-helix-leucine zipper transcription 
factors. The SREBPs differ in their tissue-specific expression, their target 
gene specificity and the relative potencies of their trans-activation 
domain. Though SREBP-1a and -1c proteins regulate gene involved in the 
g/ml) 
Diameter 
(nm) 
%  
protein 
%  
cholesterol 
% 
phospholipid 
% 
triacylglycerol 
 
HDL >1.063 5-15 33 30 29 8 
LDL 1.019-1.063 18-28 25 50 21 4 
IDL 1.006-1.019 25-50 18 29 22 31 
VLDL 0.95-1.006 30-80 10 22 18 50 
CHILOMICRON <0.95 100-1000 <2 8 7 84 
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synthesis of mono- and poly-saturated fatty acids (PUFA) and their 
incorporation into triglycerides and phospholipids, SREBP-1a is more 
potent transcription factor. The expression of SREBP-1c predominates in 
mouse liver in the fed state. Conversely SREBP-1a and SREBP-2 are 
expressed ubiquitously. SREBP-2 preferentially activates gene involved in 
the uptake and biosynthesis of cholesterol71. 
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REVERSE CHOLESTEROL TRANSPORT 
The concept of "reverse cholesterol transport" (RCT) was first introduced 
in 1968 by Glomset to describe the process by which extrahepatic 
(peripheral) cholesterol is returned to the liver for excretion in the bile and 
ultimately the feces73. The return of this "peripheral" cholesterol to the liver 
is necessary to balance cholesterol intake and de novo synthesis and 
thus to maintain whole-body cholesterol homeostasis74. The inverse 
relationship between RCT and atherosclerosis was suggested by Ross and 
Glomset75, who hypothesized that atherosclerotic lesions develop when 
an imbalance occurs between the deposition and removal of arterial 
cholesterol after endothelial injury. Some years later it was suggested that 
on the basis of the inverse relation between HDL cholesterol (HDL-C) and 
cardiovascular disease, increasing HDL should be considered as a way 
to increase clearance of cholesterol from the arterial wall to prevent 
cardiovascular disease76. In humans, approximately two-thirds of 
cholesterol is transported by low-density lipoproteins (LDLs) and ~20% by 
high-density lipoproteins (HDLs); the remaining cholesterol is carried by 
very low density lipoprotein (VLDL) particles. The risk of premature 
cardiovascular disease is positively correlated with LDL levels and 
negatively correlated with HDL levels. Cholesterol is an essential 
component of eukaryotic membrane and a fundamental precursor of 
steroid hormones and bile acids. It has been demonstrated that a 
physiological free cholesterol (FC)/phospholipid ratio in cellular 
membranes is necessary to maintain proper membrane fluidity, or more 
precisely, a proper range of membrane fluidities. Cholesterol is, in fact, 
able to reduce membrane fluidity, contrasting the effect of unsatured 
fatty acids contained in membrane phospholipids. It is abundant in the 
cellular plasma membrane and in the membrane of Golgi apparatus77, 
especially in lipid rafts, which are areas of the plasma membrane 
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enriched in proteins that participate in signal transduction78. Non-hepatic 
cells acquire cholesterol through uptake of lipoproteins and de novo 
synthesis and yet (apart from steroidogenic tissues that convert 
cholesterol to steroid hormones) are unable to catabolize it, and this 
seems to explain the physiological needs for RCT process74. Several 
studies have been demonstrated that excess unesterified cholesterol 
(FC) is toxic to cells (for review see79), and many mechanisms have been 
proposed to explain this cytotoxicity (i.e. loss of membrane fluidity, 
disruption of membrane domain, induction of apoptosis, Intracellular 
cholesterol crystallization, formation of toxic oxysterols, alteration of gene 
expression)79. Therefore, cells have developed several ways to protect 
themselves against free-cholesterol induced toxicity. One possible 
proposed mechanism is indentified in the activity of acyl-conzyme 
A:cholesterol acyltransferase, and specifically ACAT1, that transform free 
cholesterol in cholesterol ester (CE), subsequently stored in cytoplasmic 
lipid droplets, to be available for later on cell needs (for more details see 
review80 and below).  
It has been well established and clearly demonstrated that one key 
pathway, in preventing cellular cholesterol accumulation, is the efflux of 
cholesterol to extracellular "acceptors" (physiological represented by 
high density liprotein (HDL)). Cellular cholesterol efflux is the first step of 
RCT pathway, and is also considered critical and rate limiting stage for 
the entire process. Physiologically, RCT clearly occurs from all peripheral 
tissues, it has often been measured and discussed as a general 
peripheral process. More recently it has been suggested and strongly 
supported the concept to the more specific term “macrophage RCT” 
when discussing this process as it relates to atherosclerosis74. As 
explained, in atherosclerotic lesions, the primary cell type that is 
overloaded with cholesterol is the macrophage, and therefore, it makes 
more sense to conceptualize and measure RCT as a macrophage-
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specific phenomenon when the aim is to focus on its antiatherosclerotic 
characteristics74. 
The entire process of RCT can be summarized in 3 fundamentals steps:  
 
? uptake of cholesterol from cells by specific acceptors (cholesterol 
efflux)  
? HDL remodeling 
? hepatic cholesterol re-uptake through lipoprotein receptors 
 
 
 
FIGURE 2 – Schematic representation of Reverse Cholesterol Transport (from81) 
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CHOLESTEROL EFFLUX PATHWAY:  
MECHANISMS AND TRANSPORTERS INVOLVED 
 
Cellular cholesterol efflux is the transfer of FC molecule from intracellular 
compartment towards an extracellular acceptor82. There are 3 known 
mechanisms of FC flux: the aqueous passive diffusion, the accelerated 
and bidirectional SR-BI-mediated FC flux, and the unidirectional active 
transport mediated by the ATP binding cassette (ABC) transporters83.  
 
Aqueous passive diffusion occurs thanks to the sufficient hydrophilic 
properties of FC molecule. Cholesterol molecules are desorbed at the 
lipid/water interface, they diffuse through aqueous phase, and 
subsequently they are absorbed by the acceptor84. Water phase around 
the cell has been shown to represent a barrier to passive diffusion85, and 
this kind of mechanism is facilitate when the ratio FC/phospholipids is 
elevated in the cellular membrane and reduced in the cholesterol 
acceptor82. It has been demonstrated that the rate of aqueous diffusion 
can be increase by several factors able to reduce the membrane lipid-
bilayer density (i.e. high curve radius in cellular plasma membrane, low 
ratio sphingomyelin/phosphatidyl choline and levels of unsaturated 
phospholipids)85. Cholesterol efflux by aqueous diffusion occurs in every 
cell type, it is generally slow, not saturable, and inefficient in depleting 
cells from cholesterol excess. The transfer is bidirectional and regulated 
by the concentration gradient between cell and acceptor86. The rate of 
this pathway is strongly related to the structure and size of the acceptor. 
The particle size seems to have a key role, because it affects the collision 
with cholesterol molecule within aqueous phase (big size acceptor 
seems to be less efficient)84.  
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Cholesterol efflux by passive diffusion can be facilitate by plasma 
membrane proteins such as the scavenger receptor type BI (SR-BI) 83. 
Initially identified as receptor for LDL and modified LDL (i.e. AcLDL and 
OxLDL) 87, 88, it has been demonstrated that not only SR-BI is able to bind 
HDL with high affinity leading to the selective uptake of CE contained in 
these lipoprotein89, but it can also mediate cellular FC efflux towards 
phospholipid-rich acceptors like HDL90.  It is a 82-kDa membrane 
glycoprotein (509 amino acids) containing a large extracellular domain 
and two transmembrane domains with short cytoplasmic amino- and 
carboxy-terminal domains88. Major sites of SR-BI expression are the liver 
and steroidogenic glands. SR-BI is also present in other tissues and cells 
including the brain, the intestine, macrophages, endothelial cells, and 
astrocytes and it is clustered in specialized plasma membrane domains 
including caveolae, microvillar channels, and microvillar extensions91. It 
has been demonstrated that SR-BII (also called SR-BI.2) can be 
generated by the alternative splicing of SR-BI mRNA: this protein shows a 
cytoplasmic carboxy-terminal domain completely different. SR-BII has 
been shown to be strongly less efficient than SR-BI both in CE uptake 
from HDL and in cholesterol efflux to HDL. This observation suggested the 
importance of carboxy-domain for SR-BI activity92. SR-BI mediated 
cellular cholesterol efflux occurs preferentially to mature HDL, and is 
bidirectional and dependent on concentration gradient83. Several 
studies demonstrated that inhibition of HDL binding to SR-BI, by means of 
specific antibody, leaded to a big reduction of cholesterol efflux, 
suggesting that HLD-binding could be a key-role player for SR-BI 
mediated FC efflux93. It has been clearly established that SR-BI - 
mediated efflux occurs only if the phospholipids are present in the 
structure of cholesterol acceptor. Several data indicated that 
phospholipids-enrichment of HDL or total serum increased cholesterol 
efflux by SR-BI. Conversely,  efflux decreased when HDL were depleted in 
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phospholipid by the treatment with phospholipase A2 (PLA2). No cellular 
FC efflux occurs in presence of lipid-free apolipoproteins94, 95. Not only 
the quantity of phospholipids seems to affect this process, nut also the 
quality. It has been demonstrated that phosphatidyl choline-enrichment 
of HDL leaded to an higher extent increased SR-BI efflux than 
sphingomyelin-enrichment94. Nowadays, the real mechanism of action 
of this protein in mediating cellular FC efflux still remains unclear83. 
 
The ATP-binding cassette (ABC) protein ABCA1 was first cloned in 1994 
and is member of a large family of protein including 49 mammalian 
transmembrane transporters (of whom 13 are sub-classified as ABCA) 
that transport a wide diversity of substrates across the lipid bilayers in an 
energy-dependent manner96. The special role of ABCA1 in cholesterol 
efflux became apparent when it was identified as the gene that is 
mutated in Tangier disease (in its homozygous or compound 
heterozygous form)97-100. Previous study showed that cholesterol-enriched 
fibroblasts and macrophages from patients with Tangier disease lacked 
the ability to release both phospholipid and FC to lipid-free 
apolipoproteins but that efflux to mature HDL was normal101, 102. Clinical 
studies demonstrated that individuals with this pathology have almost no 
HDL cholesterol, and their apo A-I remains poorly lipidated and is rapidly 
catabolized. Thus it has been suggested and demonstrated that, in 
mediating the efflux of FC and phospholipid from cells, ABCA1 also 
mediates the lipidation of apo AI and the formation of nascent HDL (for 
review see 83, 103, 104). Pre-ß HDL generally contain 2 copies of apoA-I per 
particle and 10% by mass of lipid (free cholesterol and phospholipids). In 
contrast with passive diffusion and SR-BI mediated efflux, ABCA1 
mediates unidirectional transport of cellular phospholipid and FC using 
ATP as an energy source, and the preferred acceptor is lipid poor 
apolipoproteins such as apolipoprotein A-I (apoA-I)103. ABCs transporters 
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have been structurally classified into 2 groups: 1) whole, transporters 
having two similar structural units joined covalently; and 2) half, 
transporters of single structural units that form active heterodimers or 
homodimers105. ABCA1 (whole) is a 2,261-amino-acid integral membrane 
protein with two halves of similar structure. Each half has a 
transmembrane domain containing six helices and a nucleotide binding 
domain (NBD) containing two conserved peptide motifs known as 
Walker A and Walker B, which are present in many proteins that utilize 
ATP, and a Walker C signature unique to ABC transporters. It has been 
predicted that ABCA1 shows NH2 terminus oriented into the cytosol and 
two large extracellular loops that are highly glycosylated and linked by 
one or more cysteine bonds105. Several models have been proposed to 
explain how ABC proteins, and ABCA1 because of structure homology, 
transport amphipathic lipids out of cells 106. The flippase model seems to 
be the most correct. It involves two conformations for the transporter: (a) 
the transporter is accessible to the cytoplasmic leaflet of the plasma 
membrane where the substrate binds and (b) the substrate is released 
into the outer leaflet and thus accessible to fluid-phase acceptors106. 
Another model suggests a hydrated channel for the lipid to travel. 
However, this seems thermodynamically unlikely in the case of 
phospholipids. It has been also suggested a variation of the flippase 
model. This proposes that the substrate is transferred to the outer leaflet 
but its release is conditional on interaction of the transporter with an 
acceptor106. By means of the crystal structure obtained for the  bacterial 
Sav1866 ABC transporter a (the first of one full ABC transporter)107 it has 
been shown  an intimate interaction between transmembrane helices 
and the formation of a cavity, that is shielded from the cytoplasm and 
inner leaflet of the membrane bilayer, but accessible to the outer leaflet 
and extracellular environment. Since the cavity is lined with polar amino 
acid residues, it was suggested that transport could occur through an 
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‘extrusion’ mechanism. ATP hydrolysis could enable the transporter to 
adopt a conformation binding to the substrate on the cytoplasmic side 
of the membrane. This could occur through structural changes 
transmitted through intracellular loops that connect the transmembrane 
helices107. It has been demonstrated that many of the human mutations 
in ABCA1 are in such connecting loops, several of these loops interact 
closely with the NBD108. ABCA1 is localized both in the plasma membrane 
and intracellular compartments and it appears to target specific 
membrane domains for lipid secretion. These regions seem to be sensitive 
to accumulation of cholesterol and other lipophilic compounds that 
could feed into intracellular compartments and become substrate for 
ACAT104. ABCA1 removes cholesterol that would otherwise accumulate 
as cytosolic cholesteryl ester lipid droplets. One possibility for the link 
between ABCA1 and ACAT is that both proteins function to protect cells 
from incorporating excess free cholesterol into the endoplasmic 
reticulum where it may disrupt the peptide biosynthetic machinery104. It 
has been demonstrated that when cholesterol esterification is blocked in 
sterol-loaded macrophages, the potentially cytotoxic free cholesterol 
that accumulates is a preferred substrate for the ABCA1 pathway109. 
Regarding these observations, two models have been proposed to 
account for the ability of ABCA1 to target specific lipid domains and 
mediate cholesterol efflux. The exocytosis model implies that excess 
intracellular cholesterol is packaged into transport vesicles or rafts, 
perhaps in the Golgi apparatus, which translocate to domains in the 
plasma membrane containing ABCA1. The retroendocytosis model 
suggests that ABCA1- and apolipoprotein-containing vesicles 
endocytose to intracellular lipid deposits, where ABCA1 pumps lipids into 
the vesicle lumen for release by exocytosis104. Cross-linking experiments 
has showed that apo-AI can bind to ABCA1110, and it has been 
suggested that binding of apo-AI might be necessary but not sufficient 
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to promote cholesterol efflux104. Recent findings have suggested that 
both plasma membrane and intracellular cholesterol pool are mobilized 
by ABCA1 during apoA-I lipidation. Though the highest level of 
cholesterol and ABCA1 in plasma membrane, it has been suggested an 
important role of intracellular cholesterol pool, especially the late 
endosomal/lysosomal compartment, in mediating ABCA1 cholesterol 
efflux. The mobilization of this specific cholesterol pool by internalized 
ABCA1, and apoA-I co-internalization, suggest the possibility of 
intracellular nascent HDL formation111.  ABCA1 is widely expressed 
throughout animal tissues where it may have multiple and diverse 
functions. In humans, ABCA1 mRNA was reported to be most abundant 
in liver, placenta, small intestine, and lung. In mice, ABCA1 mRNA was 
reported to be most abundant in liver, kidney, adrenal, heart, bladder, 
testis, and brain112. Interestingly, measurements of ABCA1 protein levels in 
tissues showed discordance with mRNA abundance, in that some tissues 
with high mRNA levels (kidney, heart, bladder, and brain) had relatively 
low protein levels112. These observations are consistent with the possibility 
that posttranscriptional regulation plays a major role in tissue expression 
of ABCA1. ABCA1 expression is regulated by a variety of mechanisms (for 
review see104). Briefly: the transcription of ABCA1 is induced by nuclear 
orphan receptors, liver X receptors (LXR) or ß, and retinoid X receptor 
(RXR), alone or in combination, in which case, the effect is additive. 
Oxysterols, including 27-, 22(R)-, and 20(S)-hydroxycholesterol, are potent 
ligands of the LXR, whereas 9-cis-retinoic acid is an effective RXR 
activator. The upregulation seen with cholesterol enrichment of cells is 
also probably mediated by the LXR/RXR system. ABCA1 transcription is 
also stimulated in murine macrophages by cAMP.  Post transcriptional 
regulation of ABCA1 is afforded by apoA-I binding, which stabilizes the 
receptor and prevents its degradation, whereas unsaturated fatty acids 
seem to promote its turnover. 
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 ATP binding cassette transporter G1 (ABCG1) belongs to the ABC half-
type transporters and it is a 678-amino acid, 75.6-kDa integral protein. It 
has been proposed to act as homodimer in human and murine 
macrophages113. Other evidence has been suggested that ABCG1 may 
heterodimerise with ABCG4, as the proteins are closely related in amino 
acid sequence, and have nearly identical intron locations at their 
structural genes114. Like ABCA1, it is expressed in cholesterol loaded 
macrophages and seems to be active in cholesterol depletion, 
mediating its cellular efflux115. In cells, ABCG1 is expressed both in the 
plasma membrane and cytoplasmic compartment, and mediates the 
transport of cholesterol from cells to high density lipoprotein (HDL) but not 
to lipid-depleted apolipoprotein A-I. Moreover it has been suggested to 
be only a cholesterol transporter. 115  Conversely another study reported 
the ability of ABCA1 to mediate phospholipid cellular efflux (especially 
sphingomyelin) 116. Studies from the same research group have also 
suggested that the ABCG1-mediated efflux of cholesterol and SM is 
dependent on the cellular SM level and distribution of cholesterol in the 
plasma membrane117. It has been proposed that ABCA1 and ABCG1 
could efflux cholesterol in peripheral tissues by a synergistic relationship, 
where ABCA1 lipidates any lipid-poor/free apoA-I to generate nascent 
or pre-beta-HDL. These particles in turn may serve as substrates for 
ABCG1-mediated cholesterol export118. The transcription of ABCG1 is 
regulated by LXR/RXR system and the synthesis of oxysterols in 
macrophages seems to induce ABCG1 expression119. Moreoverit has 
been demonstrated that LXR activation induces redistribution of ABCG1 
from macrophage intracellular sites to the plasma membrane and 
increases cholesterol mass efflux to HDL in an ABCG1-dependent 
pathway120. Northern blot analyses showed abundant expression of 
ABCG1 protein in the liver, lung and spleen121, and dot blot analysis 
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revealed ubiquitous expression of ABCG1122.Several studies confirm 
significant ABCG1 mRNA expression in the brain. In situ hybridization 
studies in mouse brain indicate mRNA mRNA is widely expressed in both 
the ventricular and mantle zones of embryonic brains and in both gray 
and white matter of postnatal brains. ABCG1 was also found to be 
expressed in all cortical layers as well as in the striatum and thalamus, 
and in many different classes of neurons in the mouse CNS. qRT-PCR 
analysis and western blot analysis of human fetal brain cells indicated 
the highest ABCG1 expression in microglia followed by oligodendrocytes, 
neurons and astrocytes. (for review see123).  
 
Human ABCG5 was identified as the human homolog of the rodent 
isoform that was induced in the liver by treatment with LXR agonist, 
T0901317. ABCG5 is localized adjacent to ABCG8 on chromosome 2p21 
and seems to be coordinately regulated with ABCG8 through common 
regulatory elements (such as the nuclear receptor LXR). As consequence 
this 2 transporters have similar tissue- and cell-specific expression 
patterns124. ABCG5 and ABCG8 proteins act as heterodimeric 
transporter125, and are expressed at high levels in the canalicular 
membrane of hepatocytes, where they play an essential role in 
hepatobiliary cholesterol transport. It has been demonstrated that in 
Abcg5 Abcg8 (−/−) knockout mice biliary cholesterol concentrations are 
extremely low, compared with wild-type animals126. In addition, 
ABCG5/ABCG8 are expressed at lower levels in the apical membrane of 
enterocytes in small intestine and colon, where they limit the absorption 
of sterols from the lumen124, 127. It has been also shown that mutations in 
either ABCG5 or ABCG8 cause sitosterolemia, a rare autosomal recessive 
disorder characterised by accumulation of both plant-derived sterols 
(primarily sitosterol, but also campesterol, stigmasterol, and 
brassicasterol) and animal-derived sterol (cholesterol) in plasma and 
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tissues, leading to the development of xanthomas124, 128. Recent 
evidences seem to suggest that expression of the bile salt transporter 
ABCB4 is required for ABCG5/ABCG8-mediated biliary sterol secretion, 
suggesting that cholesterol excretion into bile requires bile salt micelles as 
cholesterol acceptor 129. 
 
 
 
Passive 
diffusion 
Figure 3 – Schematic representation of cellular cholesterol efflux (modified from130)  
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THE SECOND AND THIRD STEP OF REVERSE CHOLESTEROL 
TRANSPORT 
 
The nascent HDL particles undergo an intravascular process of 
maturation and remodeling through a several metabolic and enzymatic 
reactions. Initially, Lecithin cholesterol acyltransferase (LCAT) catalyzes 
the transfer of 2-acyl groups from lecithin to FC, generating CE (i.e. 
cholesteryl linoleate) and lysolecithin70. CE is more hydrophobic than FC 
and moves to the core of the lipoprotein particle, resulting in the 
modification of HDL particle shape. The discoidal preβ-HDL is transformed 
by LCAT activity in a more mature and spherical HDL (α-HDL)131. LCAT has 
been long proposed to play a critical role in promoting reverse 
cholesterol transport, by maintaining the correct cholesterol 
concentration gradient between cells and plasma HDL73. A defect in 
LCAT function would be expected to enhance atherosclerosis by 
interfering with this process. In a very recent review by Rader and 
Rothblat’ s group132, it has been suggested  that while LCAT is clearly 
important for HDL metabolism, it could have not such a critical role in 
macrophages reverse cholesterol transport132.  Moreover,  our group has 
recently demonstrated that serum from LCAT deficient patients show the 
same capacity of control serum to decrease the cholesterol content of 
cholesterol-loaded macrophages due to a higher efflux potential via 
ABCA1 133. HDL particles distribution appear strongly altered in carriers of 
LCAT gene mutation, being characterized by a reduced content in HDL2 
particles,  and by accumulation of preβ-HDL responsible for the greater 
ABCA1 mediated cholesterol efflux observed. The results from the study 
suggest that functional LCAT is not required for appropriate macrophage 
cholesterol depletion and RCT, since cell cholesterol can be taken up by 
discoidal preβ-HDL, and then delivered to the liver possibly through SR-
BI133. 
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In this intravascular stage of RCT, α-HDL particles undergo the activity of 
cholesteryl ester transfer protein (CETP). This enzyme is a hydrophobic 
glycoprotein, secreted by the liver and the adipose tissue that circulates 
in plasma bound to lipoprotein. CETP promote the transfer of cholesterol 
ester (CE) from HDL to LDL (only when hypertriglyceridemia is present, to 
VLDL69) in exchange for triglyceride (TG), and viceversa70. Low density 
lipoprotein return then to the liver and, interacting with LDL receptor 
release CE to hepatocytes. It has been suggested that the major part of 
HDL-CE follows this indirect pathway to be uptaken by the liver. However, 
the final step of RCT is mediated by other mechanisms, as occur in CETP 
deficient animals (e.g. mice). The most studied pathway of RCT involves 
the selective uptake of HDL-cholesterol by the hepatic SR-BI. SR-BI 
knockout mice have increased plasma HDL-cholesterol levels resulting 
from impaired hepatic uptake134, while hepatic overexpression of SR-BI 
reduced plasma HDL-cholesterol levels due to increased hepatic 
uptake135, 136. It has been demonstrated that overexpression of hepatic 
SR-BI in mice promoted macrophage RCT despite reduced plasma HDL-
cholesterol concentrations; conversely, ablation of SR-BI markedly 
reduced macrophage RCT despite increased plasma HDL-cholesterol 
concentrations137. Another mechanism proposed for the final step of RCT 
in the absence or disfunction of CETP, is the apolipoprotein E (apoE) 
enriched HDL pathway (HDLapoE). Since apoE is an effective ligand for 
LDLr, it has been proposed that HDLapoE could directly deliver CE to the 
liver interacting with LDLr138. 
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HDL PARTICLE CLASSIFICATION 
 
HDL is a class of heterogeneous lipoproteins containing characterized by 
high density (>1.063 g/mL) and small size (5–17 nm). Human HDLs contain 
two main apolipoproteins: apoA-I and apoA-II which account, 
respectively, for 70 and 20% of the HDL protein. There are also several 
minor apolipoproteins in HDL, including apoA-IV, the C-apolipoproteins, 
apoD, apoE and apoJ139, and apoM140. As mentioned above, by the 
action of different plasma and cellular factors HDLs undergo a 
continuous process of remodeling, leading to several HDL sub-
populations and fractions detectable in human blood. Several criteria 
can be used to classify HDL sub-fractions, depending on the different 
techniques for separation: 
 
• Electronic microscopy: spherical and discoidal particles 
• Density (d) gradient by ultracentrifugation:  
HDL2(1.063<d<1.125 gr/ml) and HDL3  (1.125<d<1.121 gr/ml) 
• Polyacrylamide gel separation (by size): 
HDL3c< HDL3b< HDL3a< HDL2a< HDL2b 
• Apolipoprotein composition:  
A-I HDL and A-I/A-II HDL 
• Agarose gel 2D electrophoresis:  
α, preβ and γ-migrating HDL  
 
HDL remodeling and metabolism consists of changement in lipids and 
apolipoprotein content and involves at least 10 different proteins: 
ABCA1, LCAT, SR-BI, CETP (see above), apoA-I, PLTP, LPL, HL, EL and 
cubulin140, 141. 
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Phospsholipid transfer protein (PLTP) transfers surface PL from VLDL and 
chylomicrons to HDL during TG lipolysis and accounts for most of the PL 
transfer in human plasma. PLTP remodels HDL particles into larger HDL 
particles by particle fusion, subsequently releasing apoA-I 142. Targeted 
disruption of PLTP in mice results in 60% reduction in HDL and apoA-I 
levels 143because of enhanced clearance of HDL particles. Human PLTP 
transgenic mice have increased levels of pre-β1 HDL, apoA-I and PL144. 
The role of PLTP in human pathophysiology has yet to be elucidated. 
Lipoprotein lipase (LPL) is secreted by many tissues of the body, mainly 
by adipose tissue and muscle. It is bound in the luminal surface of 
endothelial cells as homodimers to heparan sulfate proteoglycans and 
can be released by administration of heparin145. It mediates the 
hydrolysis of TG, transforming large TG-rich particles (VLDL, chylomicrons) 
into smaller TG-depleted remnant lipoproteins. Redundant surface lipid 
(FC, PL) and apolipoproteins are subsequently transferred from 
chylomicrons to HDL, increasing HDL-C and apoA-I plasmatic levels.141 
Like LPL, Hepatic lipase (HL) and endothelial lipase (EL) are two member 
of the TG lipase family141.  HL is synthesized by hepatocytes, and has 
greater activity against HDL than VLDL or chylomicrons. It converts large 
HDL2 particles into smaller HDL3 and lipid-poor apoA-I by TG hydrolysis. HL 
is most effective in hydrolyzing HDL if the HDL is TG enriched; 
hypertriglyceridemic conditions HL increases apoA-I catabolism and 
decreases HDL levels141. EL appears to have relatively more 
phospholipase activity than TG lipase activity and appears to have a 
greater preference for HDL over apoB-containing lipoproteins146.  
Levels of ApoA-I in plasma are strongly correlated with HDL levels. In 
agreement with the studies on HDL, low apoAI has been shown to be 
equivalent or better than low HDL cholesterol as a risk marker for 
atherosclerosis or cardiovascular events147, 148. Liver and intestine are the 
two major organs secreting nascent HDL as lipid-poor apoA-I or small 
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particles containing apoA-I and phospholipids and with pre-ß mobility 
on electrophoresis.  The newly secreted particles acquire additional 
cholesterol and phospholipids via ABCA1, forming pre-ß HDL. It is likely 
that pre-ß HDL particles are formed very rapidly when monomeric apoA-
I is exposed to cells.  
Although the liver is the central modulator of cholesterol homeostasis in 
the body and the major site of synthesis of apoA-I, this organ erroneously 
has not been considered as source of cholesterol for lipidation of 
circulating apoA-I and HDL biogenesis. 
Recent findings have shown that ABCA1 plays a key role in hepatic 
cholesterol efflux, inducing pathways that modulate cholesterol 
homeostasis in the liver, and establish the liver as a major source of 
plasma HDL-C. 149. By in vitro study it has also been demonstrated that 
ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL 
particle formation and decreases VLDL secretion from murine 
hepatocytes150. Moreover, the idea of liver as a major organ for HDL 
synthesis is strongly supported by the demonstration that in mice with 
specific hepatic ABCA1 disruption lead to a decrease of 80% in HDL-C, 
while the decrease in HDL induced in full ABCA1-/- mice was of 95% 151.  
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APOLIPOPROTEIN E AND APOE KNOCK OUT MOUSE MODEL 
 
The apolipoprotein E (apoE) is a 34kDa glicoprotein contained in all 
lipoproteins other than LDL, whose physiological role consists in the 
regulation of lipoprotein metabolism. Plasma apoE is mainly produced by 
the liver (>75%) and the brain is the second major organ of its synthesis.  
Macrophages also synthesize apoE 152. This apolipoprotein accomplishes 
this function mainly by promoting the hepatic clearance of HDL, VLDL, 
IDL and chylomicrons through the binding with LDL and chylomicron-
remnant receptor153 and inhibiting trygliceride lipolysis154. ApoE 
deficiency (really rare in human) or mutation causes an impairment of 
lipoprotein plasma profile, leading to hypercholesterolemia, related to 
the accumulation of chylomicron remnants in plasma and early 
development of atherosclerosis155, 156.  Mice lacking apoE (apoE-/-) 
provided the first practical model of hyperlipidemia and atherosclerosis. 
ApoE-/- mice exhibit abnormal deposition of lipids in the proximal aorta 
and liver even at 3 months of age, indicating that the lack of this 
apolipoprotein is sufficient to initiate the atherogenic process. The lesion 
development and plaque composition in apoEKO mice is also similar to 
that in humans, establishing it as an excellent animal model for studying 
the pathogenesis of atherosclerosis. A small collection of foam cells that 
are tightly adhered to the aortic valve begin to appear in mice at about 
two months of age. With time the complexity of the lesion increases to 
have fibrous caps, a necrotic core of foam cell debris, cholesterol 
crystals and calcifications. Large advanced plaques are often 
associated with the thickening of medial and adventitial tissue, 
accompanied by chronic inflammation157. The proatherogenic alteration 
in lipoprotein composition derived from apoE deficiency in mice was well 
characterized by Zhang and colleagues158: marked increase in total 
cholesterol, significant reduction in HDL-C, moderate raise of 
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triglycerides. More specific characterization of lipoprotein structure lead 
to the discovery that apoE deficient causes not only a quantitative, but 
also a qualitative modification of lipoproteins: whereas in normal mouse 
plasma HDL migrates in alpha position and VLDL/LDL in pre-beta and 
beta position, in apoE deficient mouse plasma the distribution of lipids 
shifted towards the position where lipoproteins of lower density 
migrate158. Moreover, substantial alterations in apolipoprotein content 
and distribution in lipoproteins was observed: accumulation of 
Apolipoprotein A-I (apoA-I), A-IV and B-48 in VLDL. Interestingly, the total 
amount of apoA-I is not different between normal and apoE deficient 
mice.  
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ACAT ENZYMES: STRUCTURE, TISSUE DISTRIBUTION AND 
FUNCTION 
ACAT stands for acyl-conzyme A:cholesterol acyltransferase and is an 
integral membrane enzyme located in the endoplasmic reticulum (ER) in 
a variety of cells and tissues. It catalyzes the synthesis of cholesterol esters 
(CE) conjugating a free cholesterol (FC) molecule and a fatty acyl-
CoA159. Approximately 15 years ago, two different ACAT genes (Soat1 
and Soat2) encoding for the two different ACAT enzymes (ACAT1 and 
ACAT2) have been identified. Soat1 was first identified in 1993 thanks to 
its ability to functionally complement the ACAT deficiency of a Chinese 
hamster ovary (CHO) cell mutant160. Some years later the first description 
of the effect of ACAT1 gene disruption in mice foreshowed the 
subsequent identification of a second ACAT enzyme161: these ACAT1-/- 
mice showed essentially normal hepatic cholesterol esters 
concentration, synthesis rate and response to ACAT inhibitors161. In 1998 
the Soat2 gene was simultaneously identified in monkeys, mice and 
humans162-164. Whereas the two protein isoforms catalyse the same 
chemical reaction, it has become clear that the apparent physical 
structure of the protein and the physiological role in cholesterol 
metabolism are different from one another165. Both ACAT1 and ACAT2 
are membrane-bound enzymes predicted by computer models to have 
as many as 8 transmembrane domains for ACAT1 and 7 for ACAT2162. 
Membrane topology studies have been performed by two research 
groups reporting different models for insertion of ACAT enzymes into and 
across ER.  Joyce et al. showed that ACAT1 and ACAT2 used 5 
transmembrane domains (3 of those were the same one for both 
enzymes) with serine residues essential for the activity (Ser269 and Ser249 for 
ACAT1 and ACAT2 respectively). Interestingly the developed topology 
model placed Ser269 on the cytoplasmic side of ER membrane, whereas 
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the analogous serine in ACAT2 was positioned in the ER lumen166. In other 
studies by Lin et al. 7 transmembrane domains were predicted to be 
used for ACAT1, while only 2 were predicted to be used in ACAT2167, 168. 
Different methodologies were used by the two groups, and nowadays it 
still not clear which model for the insertion of these proteins into and 
across the membrane might be correct, but both studies suggested 
fundamental structural differences between the 2 enzymes. This is 
consistent with the understanding that has been progressed from the 
discovery of the two ACAT isoforms, and that has clearly demonstrated 
their different tissue distribution and physiological function. ACAT1 mRNA 
is ubiquitously expressed in mammalian tissues: expression levels are 
highest in the adrenals glands, macrophages and sebaceous glands160, 
169, 170. Studies on non human primates indicated that ACAT1 expression 
was greatest in globet cells and interstitial macrophages of the small 
intestine, Kupffer cells of the liver, adrenocortical cells, and in cells of 
Bowman’s capsule and distal tubules in kidney171. In mice, this isoform is 
expressed at the highest level in macrophages, adrenocortical cells, 
dermal sebaceous glands and preputial glands169, 170.  Conversely, 
ACAT2 is expressed only in small intestine and liver, as demonstrated by 
studies in adult nonhuman primates4 (where the expression of ACAT2 
protein has shown to be limited to only 2 cell types, small intestinal 
enterocytes and hepatocytes171) and mice163. For several years the only 
available ACAT1 and ACAT2 localization data in human claimed that 
ACAT2 was not located in the hepatocytes of the adult liver164, 172, 173. As 
in animals, ACAT1 was demonstrated to be highly expressed in human 
atherosclerotic lesion174, in macrophages and hormone producing cell17, 
but conversely with animals171, ACAT1 was suggested to be the major 
enzyme present both in human hepatocytes and Kupffer cells, 172, 175. In 
2004 Parini at al. clearly demonstrated by that as in animals, also in the 
adult human liver ACAT2 was expressed in the ER of all hepatocytes, 
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whereas ACAT1 was only detectable within Kupffer cells176. Interestingly, 
samples analyzed in this study were snap-frozen human liver biopsy 
taken at the time of the surgery for gallstone removal, and not post 
mortem tissues as in the previous studies. Studies on the 5’-untranslated 
region of human ACAT2, from the same research group, have identified 
the hepatic nuclear factor 1 (HNF1) as one of the main transcription 
factor of this enzyme in hepatocytes elucidating the mechanisms that 
control the liver-specific expression of the human ACAT2 gene177.  In vitro 
it has been shown the possibility to find both ACAT1 and ACAT2 
expressed in HepG2 cells and Caco2 cells and some have claimed that 
isolated hepatocytes may contain both ACAT enzymes172, 173 and 
macrophages may express both178, but evidence support the fact that in 
mammals enterocytes and hepatocytes are the only 2 cell types to 
abundantly express ACAT2 without expressing detectable amount of 
ACAT1.  Both ACAT1 and ACAT2 seem to be not expressed in a 
physiological settings in the same cell types in any tissue of the body80.  
Hence, the various types of studies performed on acyl-conzyme 
A:cholesterol acyltransferase (see above)  generally support the 
likehood that ACAT1 and ACAT2 are structurally different enzymes, 
localized in different cell types, and have separate physiologic functions 
in cholesterol metabolism pathway80 (see figure 4): ACAT1, found in 
highest quantities in tissues that store cholesterol esters in cytoplasmic 
lipid droplets (i.e. maprophages), is suggested to provides essential 
“housekeeping” functions to prevent free cholesterol-induced 
cytotoxicity, in response to excessive cholesterol availability within the 
cells, and presumably to the needs of membrane function. Conversely 
ACAT2, confined in hepatocytes and small intestine enterocytes, 
synthesize cholesterol esters (mainly oleate and palmitate) that may be 
incorporated into lipid storage droplets (from which FC can be 
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regenerated) or incorporated into apoB-containing lipoproteins and 
secreted into plasma80.  
 
 
 
Figure 4 - Diagram of the separate roles of ACAT1 and ACAT2 in cholesterol metabolism 
in the liver, enterocyte, and macrophages within the artery wall (from80) 
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SPECIFIC ACAT2 INHIBITOR TO RETARD ATHEROSCLEROSIS: MAY 
BE THE FUTURE? 
After the discovery of the ACAT reaction, inhibitors of intracellular 
esterification as a means to prevent the arterial CE accumulation in 
atherosclerosis have been experimentally investigated for two decades. 
Because FC can be fluxed out from cells and incorporated in HDL, the 
rational to inhibit ACAT activity was that altering the intracellular 
cholesterol balance in favor of FC production would promote more 
efficient cholesterol efflux, activation of RCT, and deflation of 
atheroma179. A second rational for ACAT inhibition therapy approaches 
was to decrease hepatic and intestinal CEs formation, resulting in 
decreases in plasma levels of apoB-containing lipoprotein: thus the 
incorrect identification of ACAT1 as the exclusive esterifying enzyme in 
human liver172, 175 has generated incorrect physiologic models, which in 
part have contributed to wrong therapeutic approaches aimed to 
unspecific inhibition of ACAT1 and ACAT2 (see editorial179). In the clinical 
settings, ACAT inhibitors available failed the aim to retard atherosclerosis: 
this is the result demonstrate by two different clinical trials, the Avasimibe 
and Progression of Lesion on Ultrasound (A-PLUS) study, and the more 
recent ACAT Intravascular Atherosclerosis Treatment Evaluation 
(ACTIVATE) trial180, 181. As suggested by Fazio and Linton179, regarding the 
ACTIVATE outcomes, “A bold conclusion cab be drawn from the study 
by Nissen et al.: non selective ACAT inhibition in an ineffective 
antiatherosclerosis therapy and is probably harmful.” As already 
mentioned it has been demonstrated that, as in animals ACAT2 is the 
predominant cholesterol esterifying enzyme in the liver and seems to 
exclusively take part in the synthesis and secretion of CE in apoB-
containing lipoprotein, conversely to ACAT1 confined in Kupffer cells176. 
For this reason ACAT2 has been proposed as a new potential 
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therapeutic target for prevention of CVD80. Much key information has 
been learned from animals models with gene deletion of either ACAT1 or 
ACAT2. It has been demonstrated that the marked alteration in 
cholesterol homeostasis caused by ACAT1 disruption led to massive 
deposition of unesterified cholesterol in mouse skin and brain182, 183. 
Moreover, macrophages lacking ACAT1 increased atherosclerosis in 
mice with dyslipidemia, probably owing to toxic effect of free cholesterol 
and to apoptosis of macrophages in the vessel wall184, and ACAT 
unspecific pharmacological inhibition has been shown to promote rather 
than decrease atherosclerosis in mice and rabbits185. Thus, it has been 
suggested that inhibition of ACAT1 enzyme should not be aim at80. On 
the contrary, deletion of ACAT2 has been consistently atheroprotective. 
Atherosclerosis in ACAT2 deficiency was first studied in apoE/ACAT2 
double knockout mice (for review see80). ApoE/ACAT2 double knockout 
mice had greatly reduced levels of aortic atherosclerosis compared to 
the apoE single knockout controls. The lipid core of plasma apoB-
containing lipoproteins of apoE/ACAT2 double knockout mice consisted 
almost entirely of triglycerides with extremely low levels of CE. The plasma 
levels of apo-B were unchanged, suggesting that the amount of ACAT2-
derived CE present in the lipoprotein core was of vital importance. The 
protection from atherosclerosis in ACAT2 deficient mice has also been 
established in animals challenged with diets containing different fatty 
acids (FA). Regardless of the FA present in the diet (i.e n-trans FA and 
saturated FA) animals deficient for ACAT2 did not develop 
atherosclerosis186. Thus, ACAT2 plays an essential role in facilitating 
dietary fat type-specific atherosclerosis. A successful protection from 
atherosclerosis has also been obtained by decreasing the activity of 
hepatic ACAT2 in mice injected with anti-sense oligonucleotide therapy, 
which interferes with and reduces ACAT2 mRNA187. Using the same 
therapeutic approach, depletion of hepatic ACAT2 activity in mice also 
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revealed a non-biliary route for fecal cholesterol excretion188. In non-
human primates the atherogenic role for ACAT2 has been established. 
For many years, it was recognized that plasma low density lipoproteins 
(LDL) enriched in ACAT2-derived CE (cholesteryl oleate and cholesteryl 
palmitate) accumulate in the plasma of monkeys that are more 
susceptible to the development of the coronary artery atherosclerosis 
(for review see80). Subsequently, observations were made that during 
liver perfusion, the secretion rate of CE was highly correlated to the 
extent of coronary artery atherosclerosis and to the CE enrichment of 
plasma LDL, indicating a direct correlation between hepatic ACAT2 
activity and atherogenesis. In humans, several publications showed that 
higher proportions of CE derived from ACAT2 are associated with a 
increased incidence of complications from CVD80. Moreover in the 
Atherosclerosis Risk in Communities (ARIC) study, Ma et al. 189 found in 
both men and women (2872 participants) that the average carotid 
intima-media thickness (IMT) was associated significantly and positively 
with the proportion of ACAT2 derived cholesterol. Furthermore also in the 
ULSAM study, a positive association between ACAT2 derived CE 
(cholesteryl palmitate and oleate) and CVD death has been 
identified190. 
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Apolipoprotein E is a plasma protein that serves as a ligand for low 
density lipoprotein reptors. Through its interaction with these receptors, 
apoE participates actively in the transport of cholesterol and other lipids 
among various cells of the body191. Hence, apoE has been suggested to 
act as an important key-player in several critical step of the lipoprotein 
metabolism pathway. Mice lacking this apolipoprotein develop early 
and spontaneously atherosclerotic plaques. Thus, apoE-/- mice provide 
the first and one of the most useful models to study hyperlipidemia and 
atherosclerosis157. 
 
Acyl-conzyme A:cholesterol acyltransferase 2, confined in hepatocytes 
and small intestine enterocytes, synthesize cholesterol esters (mainly 
oleate and palmitate) that are incorporated into apoB-containing 
lipoproteins and secreted into plasma80. In human there are several 
indication that ACAT2-derived cholesteryl esters accumulate in plasma 
in association with coronary heart disease. In monkeys and mice, this 
accumulation has also been highly correlated with increased 
atherosclerosis80. 
 
The general aim of this work was to investigate the molecular 
mechanisms involved in lipoprotein metabolism and lipid homeostasis 
trying to further clarify the role played by these two proteins. 
Specific aim 1:  
Beyond the influence on plasma lipoprotein profile, it has been 
demonstrated that promotion of cholesterol release from foam cells is 
clearly secondary to apoE expression and secretion in macrophages, the 
most important cholesterol accumulating cells in atherosclerosis192.  Thus, 
the deletion of apoE in mice may produce an atherogenic phenotype 
also because of an impaired mobilization of cholesterol from 
macrophages. Hence, we could expect a possible negative effect on 
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the process of reverse cholesterol transport in apoE-/-. To verify this 
hypothesis we measured the macrophagic RCT in this mouse model of 
atherogenesis. 
Specific aim 2: 
Disruption ACAT2 in mice has lead to an increased triglyceride content in 
VLDL particle and to a diminished trigliceride content in the liver80. These 
findings may involve a LXRs stimulation resulting from the increased free 
cholesterol levels inside hepatocyte, as consequence of ACAT2 
deficiency. It has been extensively demonstrated that the liver x 
receptors, for which different oxysterols serve as ligand, are key players in 
the regulation of lipoprotein ad lipid metabolism. By regulating the 
expression of SREBP-1c, ACC, FAS and SCD-1, LXRs influence metabolism 
of fatty acids, triglycerides, and triglycerides rich lipoprotein. Moreover, 
similarly to what can be conceived for triglycerides secretion into VLDL, 
disruption of ACAT2 could lead to an increase in ABCA1 expression in 
hepatocytes, resulting in greater cholesterol efflux into nascent HDL.  
Thus, the aim of this part of the work was to further investigate the effect 
of specific hepatic ACAT2 knock down in mice by means of anti-sense 
oligonucleotide therapy (ASO6), trying to unmask a possible effect 
mediated by LXR stimulation and to unmask  a possible link between 
ACAT2 and HDL synthesis in mice. 
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Animals and experimental design 
IN VIVO REVERSE CHOLESTEROL TRANSPORT STUDY 
10 apoE-/- (B6.129P2-Apoetm1Unc/J) mice  and 10 C57Bl/6 (WT) mice 
(about10 week older) were used as MPM donors. Macrophagic RCT was 
quantified in apoE-/- (B6.129P2-Apoetm1Unc/J) (n=5) mice  and  C57Bl/6 
(WT) mice (n=5) as described below. 
 
ASO6 STUDY 
Male C57Bl/6 (WT) mice and male LXRa/b double knock-out (LXR doko) 
mice (on a pure C57Bl/6 genetic background) were treated for 4 weeks 
with twice a week injection (7 animals/group) of: 
– anti-sense oligonucleotide (ASO) specifically targeted to the 
hepatic ACAT2 gene (ASO6) – 25 mg/kg 
– ASO bearing a non-sense sequence (Ctrl) – 25 mg/kg  
4 weeks prior start and for all the duration of the experiment, animals 
were fed with 10% SAT (cal) and 0.2% cholesterol (w/w) diet. Animals 
were fasted for 4 hrs prior sacrifice. 
 
Quantification of Macrophagic RCT in-vivo 
Macrophagic RCT in vivo was evaluated as previously described193, but 
using murine peritoneal macrophages (MPM) instead of J774 
macrophages. After MPM harvesting, cells were incubated for 48 hours 
with [3H]-cholesterol (5 µCi) and AcLDL (100 µg/ml). Subsequently, MPM 
from wild type mice were intraperitoneally injected into wild type mice 
(WT/WT), and macrophages from apoE-/- mice were injected into apoE-
/- mice (apoE/apoE).  Mice were successively separated into individual 
cages, and  after 48 hours from the injection mice were sacrificed and 
blood and liver were collected. Plasma was separated and counted in a 
β-counter. Livers were extracted by Bligh and Dyer method and counted 
by liquid scintillation addition. Feces were collected at 24 h and 48 h 
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after the injection of radiolabeled cells extracted by the Bligh and Dyer 
method, and counted  by liquid scintillation addition. 
 
Evaluation of plasma efflux potential 
Mice were sacrificed and blood was collected from the heart, 
recovered in plastic tubes and anticoagulated with sodium citrate 3.8% 
(1 part citrate:9 part blood). Plasma was isolated by low speed 
centrifugation and stored at -80°C until use. Aliquots of plasma were 
used as acceptors in cholesterol efflux experiments. 
 
Measurement of passive diffusion and ABCA1-mediated cell cholesterol 
efflux 
Efflux by passive diffusion was measured using control J774 
macrophages. ABCA1-mediated cholesterol efflux was measured using 
control J774 macrophages and J774 macrophages treated with cpt-
cAMP to upregulate ABCA1194. Cells were grown in RPMI with 10% FCS, 
incubated at 37°C, 5% CO2, seeded in 12-well plates and utilized at 80-
90% of confluence. Monolayers were washed with PBS and incubated for 
24 h in medium containing [3H]cholesterol (4 μCi/ml). The labeling 
medium contained 1% FCS and 2 μg/ml of an ACAT inhibitor. Following 
24 h labeling period, cells were washed and incubated with 0.2% BSA, 
with or without 0.3 mM cpt-cAMP for 18 h. After this incubation, some 
wells were washed with PBS, dried, and extracted with 2-propanol; these 
cells provide baseline (time 0) values for total [3H]cholesterol content. 
Stimulated and unstimulated monolayers containing [3H]cholesterol were 
washed with PBS and incubated for efflux time (4 h) in the presence of 
2% (v/v) serum Cell media were centrifuged to remove floating cells, and 
radioactivity in the supernatant was determined by liquid scintillation 
counting. Cholesterol efflux was calculated as: (cpm in medium at 4h / 
cpm at time 0) x 100. The ABCA1-mediated cholesterol efflux was 
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calculated as the percentage efflux from stimulated J774 macrophages 
minus the percentage efflux from unstimulated J774 cells. 
 
Measurement of ABCG1-mediated cell cholesterol efflux 
CHO-K1 cells stably expressing hABCG1 were generated as previously 
described118. Parent and hABCG1-expressing cells were labeled for 24 h 
with [3H]-cholesterol, washed, and equilibrated for 90 minutes in serum-
free medium, then incubated in efflux medium containing BSA (1 
mg/mL) in the presence of 2% (v/v) serum for efflux time (6 h). Cell media 
were centrifuged to remove floating cells and cells were lysed in 0.1% 
(v/v) Triton X-100. Cells and media were assayed for radioactivity and 
cholesterol efflux in medium samples calculated as a percentage of 
total cholesterol (cells plus medium) in the culture. The ABCG1-mediated 
cholesterol efflux was then calculated as the difference between the 
percentage efflux from transfected cells minus the percentage efflux 
from CHO-K1 parent cells. 
 
Measurement of SR-BI-mediated cell cholesterol efflux 
SR-BI-mediated cholesterol efflux was measured using Fu5AH rat 
hepatoma cells, a stable highly SR-BI-expressing cell line195. Cells were 
seeded in 12-well plates and grown in DMEM medium with 5% FCS for 2 
days, and labeled with 4 μCi/ml [3H]cholesterol for 24 h in medium with 
1% FCS and 2 μg/ml of an ACAT inhibitor, to ensure that all labeled 
cholesterol was present as free cholesterol. Cells were then incubated for 
18 h with 0.2% BSA. After this incubation, some wells were washed with 
PBS, dried, and extracted with 2-propanol; these cells provide baseline 
(time 0) values for total [3H]cholesterol content. Cells were then washed 
with PBS and incubated in the presence of 2% (v/v) serum for efflux time 
(4 h). Cell media were centrifuged to remove floating cells, and 
radioactivity in the supernatant was determined by liquid scintillation 
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counting. Cholesterol efflux was calculated as: (cpm in medium at 4h / 
cpm at time 0) x 100. 
Antisense Oligonucleotides 
The 20-mer phosphorothioate oligonucleotides containing 2’-0- 
methoxyethyl groups at positions 1 to 5 and 15 to 20 with sequences 
targeted to mouse ACAT2. The sequences of these ASOs are as follows: 
ASO 6: 5’-TTCGGAAATGTTGCACCTCC-3’; ASO control: 5’-
GTCGCTCAACATCTGAATCC-3’. The ASO control is not complementary 
to the ACAT2 sequence and does not hybridize with any specific gene 
target.  
ASOs were obtained from ISIS Pharmaceuticals, Carlsbad, CA, USA, by 
means of a collaboration. 
 
Plasma lipoprotein profile  
Plasma lipoproteins were separated by size exclusion chromatography, 
and the total cholesterol, free cholesterol, triglyceride content were 
determined by a system for on-line detection 196 
 
Hepatic lipid analysis 
Liver and extracted in chloroform-methanol (2:1, v/v). 7α-hydroxy-4-
cholesten-3-one (C4) levels were determined in liver lipid extract by the 
LC-MS/MS method with 2H6-labelled C4 as internal standard as previously 
described197. Hepatic total cholesterol , cholesterol ester , free 
cholesterol , triglyceride  mass was measured in liver lipid extracts using 
enzymatic assays as described previously188, 198. Protein content was 
determined according to Lowry's method.  
 
Relative RNA expression level measurements 
Hepatic total RNA was extracted with Trizol® (Invitrogen, Carlsbad, CA) 
and reverse-transcribed into cDNA (High Capacity cDNA Reverse 
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Transcription kit, Applied Biosystem). Real-time quantitative PCR assays 
were performed in triplicate using SYBR-Green (Power SYBR Green Master 
PCR master mix, Applied Biosystem). Primers (primer sequences are 
available on request) were designed using Primer Express 2.0, all with 
sequences crossing exon-exon boundaries. Data were calculated by the 
delta-Ct method, expressed in arbitrary units, and were normalized by 
the signals obtained from the same cDNA for endogenous gene mRNA 
expression. 
 
Western Blot analysis 
3 increasing amounts of liver membranes from each mouse sample were 
separated on a NuPage 3-8% Tris-Acetate gel (Invitrogen) and then 
transferred onto nitrocellulose membranes (Invitrogen). After blocking in 
5% nonfat dry milk in PBS-T (PBS with 0.1% Tween-20), the nitrocellulose 
membranes were incubated overnight at 4°C with rabbit primary 
antibody in 5% nonfat milk powder in PBS-T. After washing with PBS-T, 
secondary antibody HPR-conjugated was added for 2 hours. The signals 
were detected using the SuperSignal chemiluminescence kit (Pierce 
Biotechnology, Inc., Rockford, IL) and a Fuji BAS 1800 analyzer (Fuji Photo 
Film Co.) and quantified by Image Gauge software (Science Lab 98, 
version 3.12; Fuji Photo Film Co.). 
 
 
Liver membrane preparation 
Liver samples (200mg) were homogenized in 3-mL ice-cold buffer 
containing 20mM Tris-HCl, 0.25 M sucrose, and  2mM MgCl2. A protease 
inhibitor cocktail (complete MINI Roche diagnostic) was added to the 
buffer before homogenization. The homogenate was then centrifuged 
for 10 minutes at 2000xg (4°C) to remove fats. The resulting intermediate 
phase was centrifuged for 45 minutes at 32000rpm by Beckman 
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Ultracentrifuge XL-70. The pellet from this spin was resuspended in 100 µl 
of Lysis Buffer containing 80 mM NaCl, 50 mM Tris-HCl, 2 mM CaCl2, 1% 
TritonX-100  and protease inhibitor cocktail, and immediately frozen at –
80°C.  
 
Isolation of microsomes and enzymatic analysis 
Liver samples (50 to 150 mg) were homogenized in 3-mL ice-cold buffer 
containing 0.1 mol/L K2HPO4, 0.25 mol/L sucrose, and 1 mmol/L EDTA, pH 
7.4. A protease inhibitor cocktail (Sigma) was added to the buffer before 
homogenization. The homogenate was then centrifuged for 15 minutes 
at 12 000g (4°C) to remove cell debris. The resulting supernatant was 
centrifuged for 60 minutes at 100 000g. The microsomal pellet from this 
spin was resuspended in 0.1 mol/L K2HPO4 at pH 7.4 and immediately 
frozen at –80°C.  
For Western blot analyses, 100 µg of microsomal protein was analyzed 
after suspension in protein solubilization buffer (120 mmol/L Tris, pH 6.8; 
20% glycerol, 4% sodium dodecyl sulfate, and bromophenol blue). 
Dithiothreitol was added to a final concentration of 100 mmol/L, and 
samples were incubated at 37°C for 30 minutes. Separation and blotting 
were performed as described earlier with the antibodies made against 
monkey enzyme N-terminal sequences199. Detection was accomplished 
by chemiluminescence, with exposure times being adjusted to maximize 
band intensity.  Total ACAT enzymatic activity was determined with 
hepatic microsomes as previously described200, except preincubation 
included a cholesterol-saturated solution of ß-hydroxypropyl cyclodextrin 
for 30 minutes before addition of 14[C]oleoyl Co-A. In separate tubes, 
pyripyropene A, a specific ACAT2 inhibitor201, was included in the 
preincubation and reaction mixture at a concentration of 5 µmol/L to 
separately identify ACAT1 (uninhibited) and ACAT2 (total–ACAT1) 
activities.  
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 2D gel electrophoresis 
Plasma HDL subclasses were separated by 2D electrophoresis, in which 
agarose gel electrophoresis was followed by non denaturing 
polyacrylamide gradient gel electrophoresis and subsequent 
immunoblotting202. In the first dimension, plasma (5 μl) was run on a 0.5% 
agarose gel; agarose gel strips containing the separated lipoproteins 
were then transferred to a 3-20% polyacrylamide gradient gel. 
Separation in the second dimension was performed at 30mA for 4 hours. 
Fractionated HDL were then electroblotted onto a nitrocellulose 
membrane and detected with an anti apoA-I antibody. 
 
Statistical analysis 
RCT and efflux results were analyzed by Student’s t test with the use of 
GraphPad Prism Software, San Diego, CA. Efflux data are reported as 
means of triplicates ± S.D.  Significance of differences in ASO6 study was 
determined for each group of values by 2-way ANOVA using Statistica 
7.0 software, StatSoft Inc., Tulsa, USA. A P value less than 0.05 was 
considered significant. 
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 REVERSE CHOLESTEROL TRANSPORT STUDY 
 
By means of a method that has been widely applied to physiological 
and pharmacological studies193, 203,  we tested the mobilization of 
radiolabeled cholesterol from macrophages, injected into the 
peritoneum of recipient mice, to plasma, liver and feces to evaluate the 
role of apoE in the antiatherosclerotic process of RCT in vivo.  In the first 
experiment, macrophages from wild type mice were injected into wild 
type mice (WT/WT), and apoE deficient macrophages were injected into 
apoE-/- mice (apoE/apoE). 48 hours after injection of MPM apoE/apoE 
showed an higher content of [3H]-cholesterol in plasma compared to 
WT/WT (FIGURE 5 (A)). Plasma total cholesterol measured by colorimetric 
method was 5 fold increased in apoE deficient mice compared to wild 
type (35.44±8.71mg/dl vs 175.43±27.39 mg/dl in WT/WT and apoE/apoE 
mice respectively).  An opposite trend was observed for [3H]-cholesterol 
measured in liver and faeces, since samples from apoE-/- mice showed a 
dramatic reduction of tracer compared to wild type (FIGURE 5 (B)/(C)). 
Total RCT, calculated as the sum of cholesterol mobilized from 
macrophages and thus detected in plasma, liver and feces, was higher 
in WT/WT mice (5.38% ±0.74vs 3.97% ±1.11Student’s t test p=0.05). These 
data indicate that reverse cholesterol transport is impaired in absence of 
apoE. 
To further investigate the role of apoE in the RCT and particularly its 
involvement in the first step, plasma from WT/WT or apoE/apoE  mice was 
tested as cholesterol acceptor. This assay was performed in different cell 
models, in order to investigate the specific mechanism of efflux involved.  
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FIGURE 5 -  Macrophage-specific RCT in vivo: Macrophage-derived [3H]-cholesterol in 
plasma (A), liver (B) and feces (C). Aliquots of plasma were counted in a β-counter. 
Samples of hepatic tissue and feces were extracted by Bligh and Dyer method in order 
to isolate the sterol fraction. Quantification of radioactivity content was performed by 
liquid scintillation counting. Results were expressed as amount of radioactivity in whole 
plasma, liver or total feces. Student’s t test *p<0.05, **p<0.01, ***p<0.001. 
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The evaluation of SR-BI-mediated efflux was assessed in rat hepatoma 
Fu5AH cells, where high amounts of this transporter are naturally 
present195. The incubation of these cells for 4 hours with 2% plasma from 
apoE/apoE promoted more efficient release of cholesterol than plasma 
from WT/WT (FIGURE 6).  
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FIGURE 6 – Plasma efflux potential by SR-BI mediated mechanism: Fu5AH were 
radiolabeled with [3H]-cholesterol, equilibrated in an albumin-containing medium and 
exposed to 2% plasma for 4h. Efflux was expressed as cpm in medium/cpm To*100. 
Student’s t test *p<0.05 
 
 
A similar trend was observed when passive diffusion- and ABCG1-
mediated cholesterol efflux were evaluated, respectively in J774 
macrophages and CHO cells (FIGURE 7 and FIGURE 8). Conversely, no 
difference in the capacity of plasma from WT/WT and apoE/apoE mice 
to drive lipid release by ABCA1 was observed (FIGURE 9).Taken together 
these results suggest that the deletion of apoE in mice, impairs the RCT in 
vivo in spite of an increase in plasma efflux potential.  
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FIGURE 7 - Plasma efflux potential by acqueous passive diffusion: J774 macrophages 
were radiolabeled with [3H]-cholesterol, equilibrated in an albumin-containing medium 
and exposed to 2% plasma for 4h. Efflux was expressed as cpm in medium/cpm To*100. 
Student’s t test *p<0.05 
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FIGURE 7 - Plasma efflux potential by ABCG1 mediated mechanism: Parent and 
hABCG1-expressing CHO cells were radiolabeled with [3H]-cholesterol, equilibrated in 
an albumin-containing medium and exposed to 2% plasma for 4h. The ABCG1-
mediated cholesterol efflux was then calculated as the difference between the 
percentage efflux from transfected cells minus the percentage efflux from CHO parent 
cells Efflux was expressed as cpm in medium/cpm To*100. Student’s t test *p<0.005 
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FIGURE 9 - Plasma efflux potential by ABCA1 mediated mechanism: J774 macrophages 
were radiolabeled with [3H]-cholesterol, equilibrated in an albumin-containing medium 
in presence of cpt-cAMP 0.3mM and exposed to 2% plasma for 4h. Efflux was expressed 
as cpm in medium/cpm To*100.  
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ASO6 STUDY 
 
We initially measured the SOAT2 mRNA levels in the liver by RT-PCR, and 
the expression of ACAT2 protein in liver microsomes by western blot 
analysis. As expected, ASO6 led to a reduction of ACAT2 both at mRNA 
and protein levels, in both WT and LXR double knockout mice (FIGURE 
10).  Analysis of ACAT2 activity in liver microsomes showed a significant 
reduction in both animal strains treated with ASO6 (Student’s t test 
p<0.001), while ACAT1 activity was not affected by the anti-sense 
oligonucleotide treatment (FIGURE 11). It should be pointed out that the 
ACAT1 activity observed in the hepatic microsomal fraction is the 
contribution of 
Kupffer cells present in the liver:  ACAT1 is confined  only to these cells 
whereas ACAT2 only to hepatocytes (for review see80). LXRα mRNA 
expression in the liver was slightly decreased in WT mice treated with 
ASO6 (p<0.05), while LXRβ expression was not affected by ACAT2 
disruption. As expected both LXR genes were absent in LXR DOKO mice. 
(FIGURE 12 ) 
 
 
FIGURE 10 – Effect of ASO6 treatment on ACAT2 mRNA and protein expression in the 
liver: mRNA expressions were analyzed by real-time RT-PCR. Data are standardized for 
TFIIB mRNA expression and normalized to WT Ctrl. 2-way ANOVA, ***p<0,001. Western 
blot analysis was performed on liver microsomes as described in methods. 
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FIGURE 11 – Effect of ASO6 treatment on ACAT2 and ACAT1 activity in liver microsomes 
(for details see methods). Student’s t test ***p<0.001 
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 FIGURE 12 – Effect of ASO6 treatment on LXRα and LXRβ gene expression in the liver: 
mRNA expressions were analyzed by real-time RT-PCR. Data are standardized for TFIIB 
mRNA expression and normalized to WT Ctrl. 2-way ANOVA, *p<0.05 ***p<0.001.  
 
 
 
 
PLASMA LIPOPROTEIN PROFILE 
The analysis of plasma lipoprotein fractions revealed that ASO6 led to a 
slight increase in HDL-total cholesterol and to a clear increase in HDL-free 
cholesterol content. The latter was more pronounced in LXR DOKO mice 
(FIGURE 13 (A)/(B)).  Serum triglycerides were increased in apoB-
containing lipoprotein fraction by ACAT2 down-regulation, and this 
effect was clearly not LXR-dependent (FIGURE 13 (c))  
 65 
 FIGURE 13 – Plasma lipoprotein profile: (A) Total cholesteol, (B) Free cholesterol, (C) 
Triglycerides. Plasma lipoproteins were separated by size exclusion chromatography, 
and the TC, FC, TG content were determined by a system for on-line detection 196 
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LIVER LIPID COMPOSITION 
Hepatic total cholesterol content was about 4 fold higher in LXR DOKO 
mice than in WT (390.04 ± 38.8 mg /gr Protein vs. 92.21 ± 8.44 mg/gr 
Protein, n=6,  2-way ANOVA p<0.001). ASO6 treatment lead to a 71% and 
24% decrease of hepatic TC in WT and LXR DOKO mice, respectively 
(FIGURE 14 (A)) ACAT2 down-regulation did not affect the hepatic free 
cholesterol content both in WT and LXR DOKO mice.  The latter showed a 
significantly increased FC amount compared to WT (FIGURE 14 (B)). Also, 
cholesteryl ester levels were 4.6-fold higher in the liver of LXR DOKO mice 
than in WT.  In WT mice, ASO6 treatment reduced hepatic CE levels by 
90%, while only a 29% reduction was observed in LXR DOKO mice 
receiving ASO6 (FIGURE-14 (C)). In WT mice hepatic TG were about 7.5 
fold higher than in LXR DOKO. ACAT2 down-regulation lead to a modest 
reduction in hepatic TG content (22% and 38% reduction in WT and LXR 
DOKO mice respectively). (FIGURE-14 (D)).   
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FIGURE 14 – Effect of ASO6 treatment on liver lipid composition. Hepatic total cholesterol 
, cholesterol ester , free cholesterol , triglyceride  mass was measured in liver lipid 
extracts by enzymatic assays. 2-way ANOVA, *p<005, ***p<0.001 
 
 
ANALYSIS OF HEPATIC GENE AND PROTEIN INVOLVED IN LIPID 
HOMEOSTASIS  
Down-regulation of hepatic ACAT2 activity by ASO treatment should 
affect to the pool of free cholesterol that can signal to and determine a 
down-regulation of the SREBP-system. This indeed led to down regulation 
of the expression of the gene limiting cholesterol synthesis, but only in WT 
mice. If no differences in hepatic expression of 3-hydroxy-3-methyl-
glutaryl-CoA reductase and synthase between the two different 
genotypes, ASO6 treatment lead to reduction of mRNA expression of 
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these two genes only in WT  mice (FIGURE 15 (A)/(B)). A similar trend was 
observed also for LDLr and PCSK9 mRNA: significant reduction induced 
by ACAT2 down-regulation was shown in WT group, while in LXR DOKO 
mice no statistically significant effects were seen (FIGURE 15 (C)/(D)).  
Despite the higher decrease in PCSK9 expression, compared to the 
decrease in LDLr expression, the net effects of ASO6-tretamnet was a 
down regulation of LDLr protein expression in liver membranes of WT 
mice (46% decrease)(FIGURE 16). Interestingly, we found that LXR DOKO 
mice showed undetectable levels of LDLr protein in liver membranes by 
western blot analysis (FIGURE 16).   
 
 
 
FIGURE 15 – Effect of ASO6 treatment on hepatic gene esxpression: (A) HMG-CoA 
reductase, (B) HMG-CoA Synthase, (C) LDL receptor, (D) PCSK9. mRNA expressions were 
analyzed by real-time RT-PCR. Data are standardized for TFIIB mRNA expression and 
normalized to WT Ctrl. 2-way ANOVA, **p<0.005 ***p<0.001.  
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FIGURE 16 – Effect of ASO6 treatment on LDLr protein expression in liver membrane. 
 
 
 
Quantification of mRNA by RT-PCR of the genes involved in bile acids 
synthesis and cholesterol transport revealed that ASO6 had no effect on 
the hepatic mRNA levels of CYP7A1, ABCG5 and ABCG8, both in WT and 
LXR DOKO mice. As expected, all these gene were down regulated  in 
LXR DOKO mice compared to WT (FIGURE 17 (A)/(C)/(D)) Small 
heterodimer partner (SHP) mRNA expression was similar in both 
genotypes, and ASO6-treatment resulted in a down-regulation only in 
LXR DOKO mice (FIGURE 17 (B)). Quantification of 7α-hydroxy-4-
cholesten-3-one (C4), a surrogate marker for bile acid synthesis, in 
hepatic lipid extract showed an increase following ASO6-treatment both 
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in WT and LXR DOKO mice (FIGURE 18). As expected and consequence 
of CYP7A1 down-regulation, C4 levels were significantly lower and the 
increase by ASO6-treatment smaller in LXR DOKO mice when comparet 
to WT animals.  
 
 
 
 
 
 
 
FIGURE 17 – Effect of ASO6 treatment on hepatic mRNA expression of gene involved in 
bile acids synthesis and cholesterol transport: (A) Cyp7A1, (B) SHP, (C) ABCG8, (D) 
ABCG5. mRNA expressions were analyzed by real-time RT-PCR. Data are standardized 
for TFIIB mRNA expression and normalized to WT Ctrl. 2-way ANOVA, *p<0.05, **p<0.005. 
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FIGURE 18 – Quantification of 7α-hydroxy-4-cholesten-3-one (C4) in the liver. Data are 
corrected  for hepatic total cholesterol content, and expressed as Mean value for 
each group (n=6) ± SEM, 2-way ANOVA *p<0.01, **p<0.005. 
 
 
 
Hepatic mRNA levels of the gene involved in cholesterol efflux from 
hepatocytes (i.e. ABCA1, and SR-BI) were not affected by 
oligonucleotide therapy (FIGURE 19), but ASO6 lead to an increase of 
ABCA1 and SR-BI protein in the liver membrane from both animal 
genotypes. SR-BI protein was increased by treatment of 28% and 27% for 
WT and LXR DOKO respectively (FIGURE 20).  
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FIGURE 19 – Effect of ASO6 treatment on hepatic mRNA expression of  cholesterol 
transport er gene(A) SR-BI, (B) ABCA1. mRNA expressions were analyzed by real-time RT-
PCR. Data are standardized for TFIIB mRNA expression and normalized to WT Ctrl.  
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FIGURE 20 – Effect of ASO6 treatment on SR-BI protein expression in liver membrane. 
 
 
Interestingly, ASO6 lead to a 134% increase of ABCA1 protein in liver 
membrane from WT mice and to a higher increase (188%) in LXR DOKO 
liver membranes (FIGURE 21).  Although the minor effects seen for 
triglyceride content in the liver (see above), ASO treatment led to down-
regulation of all the gene involved in fatty acid synthesis, likely mediated 
by a SREBP1-c down-regulation (i.e. Fatty acid synthase, hepatic 
stearoyl-CoA deaturase 1 and acetyl-CoA carboxylase 1)(FIGURE 22).  
Triacylglycerol hydrolase 1 and 2 mRNA expression resulted significantly 
reduced in LXR DOKO KO mice compared to WT, suggesting TGH-1 and 
TGH-2 as new LXR gene target. ASO6 did not seem to affect the 
expression of this gene in WT mice, while in LXR DOKO mice ACAT2 
down-regulation lead to a slight increase of TGH-1 mRNA and a 
decrease in TGH-2 mRNA levels (FIGURE 23). 
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FIGURE 21 – Effect of ASO6 treatment on ABCA1 protein expression in liver membrane. 
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FIGURE 22 – Effect of ASO6 treatment on hepatic mRNA expression of  genes involved in 
fatty acid synthesis: (A) fatty acid synthase, (B) stearoyl-CoA deaturase 1, (C) acetyl-
CoA carboxylase 1. mRNA expressions were analyzed by real-time RT-PCR. Data are 
standardized for TFIIB mRNA expression and normalized to WT Ctrl. 
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FIGURE 23 – Effect of ASO6 treatment on hepatic mRNA expression of Triacylglycerol 
hydrolase 1 (A) and 2 (B)  mRNA expressions were analyzed by real-time RT-PCR. Data 
are standardized for 18S mRNA expression and normalized to WT Ctrl.  
 
 
 
 
 
 
 
HDL subpopulation distribution 
Since the observed increase in plasma HDL-C and ABCA1 protein in the 
liver secondary to ACAT2 down-regulation, we decided to analyze 
mouse sera by 2D-gel electrophoresis to identify possible changes in HDL 
sub-fractions. In WT mice ASO6 treatment did not affect small pre-beta 
HDL percentage (FIGURE 24), but lead to clear changes in HDL 
subpopulation distribution: HDL becomes more heterogeneous, with the 
appearance in the alpha region of particles of lager size (FIGURE 25). A 
different trend was observed in LXR DOKO mice, in which ASO6 
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treatment induced a significant increase in pre-beta HDL percentage 
(FIGURE 24) and to a shift of the alpha HDL towards smaller size particles 
(FIGURE 25). 
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FIGURE 24 –  % of total apoA-I in preβ  HDL subfraction. Student’s t test p<0.05  
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FIGURE 25 –  HDL subclasses. HDL subclasses were separated by 2D electrophoresis and 
transferred onto a nitrocellulose membrane, on which lipoproteins were detected with 
an anti apoA-I antibody. 
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DISCUSSION 
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IN-VIVO REVERSE CHOLESTEROL TRANSPORT STUDY 
 
The atheroprotective role of apoE is well documented by several works, 
showing the impact of its deletion on atherosclerosis development. This 
activity is at least in part related to the modulation of lipoprotein profile, 
but it has been shown that independently of this, apoE selective 
expression in macrophages protects towards the development of 
atherosclerosis in hypercholesterolemic mice. Since RCT is an 
antiatherosclerotic process possibly influenced by circulating lipoprotein 
(particularly HDL) we aimed to evaluate apoE role in this physiological 
pathway. We manage a method that allows the determination of RCT 
that occurs specifically from macrophages. Here we used peritoneal 
macrophages from WT or apoE-/- mice enriched with 3H-cholesterol and 
injected into WT or apoE deficient mice respectively. Cholesterol is 
delivered from macrophages to the plasma compartment and 
successively returns to the liver and feces. The quantification of 
radioactivity in plasma, liver and faeces allows to measure every single 
step of RCT. The amount of radioactivity in plasma is significantly higher in 
apoE/apoE mice, consistent with increased level of circulating 
lipoproteins. In contrast, reduced amount of cholesterol in liver and feces 
was detected, consistent with previously published data showing that 
apoE KO mice present a reduced uptake of CE-HDL204 and that apoE 
promotes biliar excretion205. The quantification of total RCT, estimated as 
the sum of radioactive cholesterol in plasma, liver and feces, revealed 
that more radioactivity is mobilized within WT/WT mice, indicating that 
the whole process is impaired in absence of apoE. To investigate 
whether increase of lipid efflux may account for the increased RCT in 
WT/WT mice, we tested plasma capacity to drive cholesterol release 
from cells. However, cholesterol efflux to apoE KO mice plasma by 
passive diffusion, SR-BI and ABCG1 was improved. This probably reflects 
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the higher content of apoB-containing lipoproteins, that are known to be 
good and efficient acceptors of cholesterol through these mechanisms. 
However, it should be reminded that passive diffusion and SR-BI-
mediated efflux are bidirectional processes, whose global effect 
depends on lipid concentration gradient between cells and acceptors. 
It is therefore conceivable that apoE/apoE mouse plasma is also able to 
promote lipid influx, thus enriching cell cholesterol content. Conversely, 
plasma capacity to drive ABCA1-mediated efflux was similar in both 
animal groups.   
 
Taken together these results suggest that apoE essential for a functional 
RCT. 
 
 
ASO6 STUDY 
 
Inhibition of intracellular esterification of cholesterol as a means to 
prevent the arterial CE accumulation in atherosclerosis has for many 
years been considered as potential strategy. Much key information has 
been learned from mice with gene deletion either of ACAT1 or ACAT2. In 
hypercholesterolemic ACAT1-/- animals, the ACAT1 deficiency led to a 
marked alteration in cholesterol metabolism leading to massive 
accumulation of unesterified cholesterol causing numerous skin and 
brain lesions. The atherosclerotic lesions in the apoE-/- and LDLr-/- mice 
lacking ACAT1 had reduced levels of neutral lipids and a paucity of 
macrophages which may reflect cell death via apoptotic mechanisms 
182. On the contrary, deletion of ACAT2 has been consistently 
atheroprotective (for review see80). A successful protection from 
atherosclerosis has been obtained by decreasing the activity of hepatic 
ACAT2 in mice injected with anti-sense oligonucleotide therapy, which 
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interferes with and reduces ACAT2 mRNA187.  Using the same therapeutic 
approach in the present work we investigated the role of hepatic ACAT2 
disruption in triglyceride and cholesterol metabolism in LXRα/β double 
knock-out mice and in wild type mice fed with 10% SAT (cal) and 0.2% 
cholesterol (w/w) diet. The use of these two animal models was aimed to 
find a possible LXR activation secondary to ACAT2 inhibition. No evident 
LXR activation followed down-regulation of hepatic ACAT2 activity by 
ASO treatment in male mice. In WT mice ASO6 seemed to affect the 
pool of free cholesterol that could signal to and determine a down-
regulation of the SREBP-system.  Indeed, the effect observed in this 
animal group was a decreased mRNA expression of HMG-CoR, HMG-
CoS. ASO6 led also to a down-regulation LDLr mRNA and to a higher 
extent decrease in PCSK9 expression. Nevertheless, the net effect was a 
down regulation of LDL-receptor protein expression in liver membranes 
from WT mice.  Interestingly, we found that LXR DOKO mice showed 
undetectable levels of LDLr protein in liver membranes by western blot 
analysis, suggesting a defect in LDLr recycling (more work will have to be 
performed to confirm this hypothesis).  Furthermore in wild-type mice, the 
lack of LXR activation and the down-regulation of the SREBP-system after 
ASO treatment suggest that LXRs are not sensitive to phisologic variation 
of cholesterol levels within the cell, conversely to the SEBRP-system.  
It has been demonstrated that disruption of ACAT2 in mice leads to 
increased plasma triglyceride to reduced hepatic triglyceride (for review 
see80). In the present study serum triglycerides were increased in apoB-
containing lipoprotein fraction by ACAT2 down-regulation, and this 
effect was clearly not LXR-dependent.  Curiously, hepatic ACAT2 knock 
down led only to a modest reduction in hepatic TG content both in WT 
and LXR DOKO mice. Never the less ASO treatment led to down-
regulation of all genes involved in fatty acid synthesis, likely mediated by 
the SREBP1-c down-regulation.   
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As described above, animals were on a 10% SAT (cal) and 0.2% 
cholesterol (w/w) diet four weeks prior start and for all the duration of 
ASO6 treatment. This condition probably caused a strong hepatic fat 
load, leading to the observed partial effect of ASO treatment  in 
reducing liver TG content. We demonstrated that cholesteryl ester levels 
were 4.6-fold higher in the liver of LXR DOKO mice than in WT, and ASO6 
treatment reduced hepatic CE levels by 90% in WT animals, while only a 
29% reduction was observed in LXR DOKO mice receiving ASO6. For the 
first time we identified TGH1 and TGH2 as new LXR-target gene. Since it 
has been shown that triacylglycerol hydrolase catalyses not only the 
hydrolysis of TG but also of CE,  TGH1 and TGH2  reduced expression 
observed in LXR DOKO may explain the elevated hepatic CE-content in 
the livers of LXR DOKO mice. ACAT2 down-regulation did not affect the 
hepatic free cholesterol content both in WT and LXR DOKO mice. Similar 
results were shown in a recent mouse study using the antisense 
oligonucleotide approach for hepatic ACAT2 activity down-
regulation206. In this elegant study, depletion of hepatic ACAT2 resulted 
in reduced packaging of cholesterol into apoB-containing lipoprotein, 
whereas HDL levels remained unchanged. Despite the reduced CE 
accumulation in the liver of ASO treated mice, no hepatic  free 
cholesterol accumulation occurred and neutral fecal sterol excretion 
was promoted206. Brown et al. supported the concept that when hepatic 
cholesterol esterification is limited, the liver doesn’t deal with FC burden 
by a new mechanism where none of the traditional pathway (i.e. 
repression of the novo synthesis, conversion to bile acid, efflux into 
nascent HDL) are involved206. They proposed a non-biliary route for fecal 
cholesterol excretion206.  Our work was also aimed to unmask a possible 
link between ACAT2 and HDL synthesis in  mice. In a recent study on 
gallstone and gallstone-free patients we demonstrated a significant 
negative correlation between the hepatic ACAT2 activity and the 
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plasma levels of HDL cholesterol and apoA-I (manuscript in preparation). 
This important finding is in line with the hypothesis that when hepatic 
ACAT2 is low, free cholesterol may be fluxed through ABCA1 to apoA-I 
and thus increasing nascent HDL particles. It should be also reminded 
that the study by Brown et al. 206 was performed on apoB100only/LDLr-/- 
mice: being apoB-100 highly expressed and LDLr lacking, the resulting 
elevated secretion of VLDL and the dramatically decreased LDL-
clearance could mask the positive effect of ACAT2 inhibition on HDL-C 
mediated by the ABCA1 pathway:  FC could be forced into the larger 
amount of apoB-100-containig particles or utilized as substrate for bile 
acid synthesis rather than be fluxed into nascent HDL.   
In the present work we demonstrated that down-regulation of hepatic 
ACAT2 activity is coupled to an  increase in protein expression of ABCA1 
in the liver, providing us with the mechanism by which ACAT2 may 
regulate HDL levels in plasma.  Indeed the analysis of plasma lipoprotein 
profile revealed that ASO6 treatment led to a slight increase in HDL-total 
cholesterol and to a clear increase in HDL-free cholesterol content. 
Moreover in WT mice ASO6 treatment did not affect small pre-beta HDL 
percentage, but lead to clear changes in HDL subpopulation distribution: 
HDL becomes more heterogeneous, with the appearance in the alpha 
region of particles of lager size.  A different trend was observed in LXR 
DOKO mice, in which ACAT2 down-regulation induced a significant 
increase in pre-beta HDL percentage and to a shift of the alpha HDL 
towards smaller size particles.   
 
In conclusion, the use of anti-sense oligonuclotide targeted to hepatic 
ACAT2 revealed a new pathway by which the liver contributes to HDL 
metabolism and identify ACAT2 as an important intracellular hepatocyte 
player in the determination of cholesterol fluxes either into apoB-
containing lipoprotein secretion or into apoAI lipoprotein synthesis. 
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A B B R E V I A T I O N S 
 
ABCA1  ATP-binding cassette A1 
ABCG1   ATP-binding cassette G1 
ABCG5   ATP-binding cassette G5 
ABCG8   ATP-binding cassette G8 
ACAT   acyl-CoA:cholesterol acyltransferase 
ACC1   acetyl-CoA carboxylase 1 
AcLDL   acetylated LDL 
apoA-I   apolipoprotein A-1 
apoB    apolipoproteinB 
apoE    apolipoprotein E 
ASO    antisense olionucleotide 
C4    7α-hydroxy-4-cholesten-3-one  
Ca    calcium 
CE    cholesteryl ester 
CETP    cholesterol ester transfer protein 
Cyp7a   cholesterol 7 alpha hydroxylase 
EC    endothelial cell 
EL    endothelial lipase 
ER    endoplasmic reticulum 
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FA    fatty acid 
FAS     fatty acid synthase 
FC    free cholesterol 
glycLDL   glycosilated LDL 
HDL    high-density lipoprotein 
HDL-C   HDL cholesterol 
HL    hepatic lipase 
HMG-CoR    3- hydroxymethyl glutaryl coenzyme A reductase 
HMG-CoS  3- hydroxymethyl glutaryl coenzyme A synthase 
ICAM  intracellular adhesion molecule 
IDL    intermediate density lipoprotein 
IL    interleukins 
INSIG    insulin inducible gene 
IR    insulin receptor 
LCAT    lecithin:cholesterol acyl transferase 
LDL    low-density lipoprotein 
LDLr    low-density lipoprotein receptor 
LOX-1   lectin-like oxidized low-density lipoprotein receptor-1 
Lp (a)   lipoprotein (a) 
LPL    lipoprotein lipase 
LPS    lipopolysacchride 
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LXR    liver X receptor 
LXRE    LXR response elements 
MCP-1   macrophage chemotactic protein 
MCSF  macrophage colony-stimulating factor 
MMPs   matrix metalloproteinases 
MPM   murine pedritonel macrophages 
MTTP    microsomal triglyceride transfer protein 
NBD    binding domain 
NFkB    nuclear factor-kappa B 
NO    nitric oxide 
NPC    Niemann-Pick type C 
OxLDL   oxidized LDL 
PLA2    phospholipase A2  
PLC    Phospholipase C 
PLTP    phospholipid transfer protein PLTP 
PPAR    peroxisome proliferator-activated receptors 
PUFA    poly-unsaturated fatty acids  
RCT    reverse cholesterol transport 
RXR    retinoid X receptor 
SCAP   SREBP cleavage activating protein 
SCD-1   stearoyl CoA desaturase 
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SHP    Small heterodimer partner 
SMC    smooth muscle cells 
SR-B1    scavenger receptor B-1 
SREBP   sterol response element-binding protein  
TC    total cholesterol 
TG    triglyceride 
TGH1    Triacylglycerol hydrolase 1 
TGH2    Triacylglycerol hydrolase 2 
TLR    Toll-like receptor 
VCAM   vascular cell adhesion molecule 
VLDL    very low density lipoprotein 
VLDLr    VLDL receptor  
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